1
|
Silverstein J, Suleiman L, Yau C, Price ER, Singhrao R, Yee D, DeMichele A, Isaacs C, Albain KS, Chien AJ, Forero-Torres A, Wallace AM, Pusztai L, Ellis ED, Elias AD, Lang JE, Lu J, Han HS, Clark AS, Korde L, Nanda R, Northfelt DW, Khan QJ, Viscusi RK, Euhus DM, Edmiston KK, Chui SY, Kemmer K, Wood WC, Park JW, Liu MC, Olopade O, Leyland-Jones B, Tripathy D, Moulder SL, Rugo HS, Schwab R, Lo S, Helsten T, Beckwith H, Berry DA, Asare SM, Esserman LJ, Boughey JC, Mukhtar RA. Abstract P2-14-01: The impact of local therapy on locoregional recurrence in women with high risk breast cancer in the neoadjuvant I-SPY2 TRIAL. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p2-14-01] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: In women with breast cancer receiving neoadjuvant chemotherapy, residual cancer burden (RCB) predicts distant recurrence and survival. In those with high risk tumors, locoregional recurrence (LRR) remains a concern, and has been associated with type of local therapy received. We evaluated the impact of local therapy on LRR in the ISPY-2 TRIAL.
Methods: Data were analyzed in Stata 14.2, using Chi2 test, log rank test, and a Cox proportional hazards model. RCB was considered a categorical variable (0/1 versus 2/3), as described in prior publications. Breast surgery categories were lumpectomy +/- radiotherapy, or mastectomy +/- radiotherapy. Axillary surgery was defined as sentinel lymph node (SLN) surgery (≤6 nodes removed) or axillary dissection (>6 nodes).
Results: Follow up data from the I-SPY2 TRIAL were available for 630 patients (median follow up 2.76 yrs, range 0.4-7.2). Type of local therapy was significantly associated with clinical stage at presentation, with stage III patients most frequently undergoing mastectomy + radiation (p<0.001). Women with higher RCB were more likely to undergo mastectomy than those with lower RCB (61.3% vs 48.8% mastectomy rate, p=0.002), and more likely to receive adjuvant radiotherapy (62.0% vs 53.9%, p=0.048). There was no association between clinical stage, type of surgery, or radiotherapy and LRR (Table). Higher RCB was significantly associated with LRR, with 3 year locoregional recurrence free rate of 95.1% in RCB 0/1 versus 89.9% in RCB 2/3 (p=0.003).
In a Cox model adjusting for clinical stage, tumor subtype, surgical therapy, RCB status, nodal radiation, and age, significant predictors for LRR were tumor subtype and RCB status. Hazard ratio (HR) for LRR in those with RCB 0/1 was 0.39 compared to those with RCB 2/3 (95% CI 0.17-0.87, p=0.021). There was no difference in LRR between breast conservation and mastectomy; within the breast conservation group, those who had lumpectomy alone had higher hazard of LRR compared to those having lumpectomy + radiation (HR 3.1, 95% CI 1.1-9.2, p=0.043).
Conclusions: Extent of surgical therapy was not associated with local tumor control, regardless of advanced tumor stage at presentation. Rather, tumor biology and response to therapy were the best predictors of LRR. These data highlight the opportunity to minimize the morbidity of extensive surgical therapy for patients with excellent response to systemic therapy.
LRR rates by clinical features and treatment status FrequencyLRR RateP valueClinical Stage 0.5I240 (47.5%)5.8% II185 (36.6%)8.7% III80 (15.8%)6.3% Tumor Subtype 0.014ER+PR+Her2-161 (26.4%)3.1% ER+PR-Her2-56 (9.2%)3.6% Her2+176 (28.9%)6.3% Triple negative216 (35.5%)11.1% Local therapy 0.169Lumpectomy85 (13.5%)11.8% Lumpectomy with radiation198 (31.4%)5.6% Mastectomy173 (27.5%)5.2% Mastectomy with radiation174 (27.6%)8.6% Axillary surgery 0.23None5 (0.8%)20% SLN329 (52.2%)5.8% ALND296 (47%)8.5% Axillary radiation 0.535Yes42 (6.7%)9.5% No588 (93.3%)7.0% Axillary management 0.2No surgery or radiation5 (0.8%)20.0% SLN312 (50%)5.3% SLN+Axillary radiation17 (2.7%)8.3% ALND271 (43%)10.3% ALND+Axillary radiation25 (4%)5.4% RCB 0.0020/1293 (50.1%)3.8% 2/3292 (49.9%)10.3%
Citation Format: Silverstein J, Suleiman L, Yau C, Price ER, Singhrao R, Yee D, DeMichele A, Isaacs C, Albain KS, Chien AJ, Forero-Torres A, Wallace AM, Pusztai L, Ellis ED, Elias AD, Lang JE, Lu J, Han HS, Clark AS, Korde L, Nanda R, Northfelt DW, Khan QJ, Viscusi RK, Euhus DM, Edmiston KK, Chui SY, Kemmer K, Wood WC, Park JW, Liu MC, Olopade O, Leyland-Jones B, Tripathy D, Moulder SL, Rugo HS, Schwab R, Lo S, Helsten T, Beckwith H, I-SPY 2 TRIAL Consortium, Berry DA, Asare SM, Esserman LJ, Boughey JC, Mukhtar RA. The impact of local therapy on locoregional recurrence in women with high risk breast cancer in the neoadjuvant I-SPY2 TRIAL [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-14-01.
Collapse
Affiliation(s)
- J Silverstein
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - L Suleiman
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - C Yau
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - ER Price
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - R Singhrao
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - D Yee
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - A DeMichele
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - C Isaacs
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - KS Albain
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - AJ Chien
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - A Forero-Torres
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - AM Wallace
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - L Pusztai
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - ED Ellis
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - AD Elias
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - JE Lang
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - J Lu
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - HS Han
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - AS Clark
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - L Korde
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - R Nanda
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - DW Northfelt
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - QJ Khan
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - RK Viscusi
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - DM Euhus
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - KK Edmiston
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - SY Chui
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - K Kemmer
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - WC Wood
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - JW Park
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - MC Liu
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - O Olopade
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - B Leyland-Jones
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - D Tripathy
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - SL Moulder
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - HS Rugo
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - R Schwab
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - S Lo
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - T Helsten
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - H Beckwith
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - DA Berry
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - SM Asare
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - LJ Esserman
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - JC Boughey
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | - RA Mukhtar
- University of California, San Francisco, San Francisco, CA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; Georgetown University, Washington, DC; Loyola University, Maywood, IL; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, La Jolla, CA; Yale Cancer Center, New Haven, CT; Swedish Cancer Institute, Seattle, WA; University of Colorado, Denver, Aurora, CO; University of Southern California, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; CTEP, National Cancer Institute, Bethesda, MD; The University of Chicago Medical Center, Chicago, IL; Mayo Clinic, Scottsdale, Scottsdale, AZ; University of Kansas, Westwood, KS; University of Arizona, Tucson, AZ; Johns Hopkins Medicine, Dallas, TX; Inova Health System, Fairfax, VA; Genentech, Portland, OR; Oregon Health & Science University, Portland, OR; Emory University, Atlanta, GA; Mayo Clinic, Rochester, Rochester, MN; Avera Cancer Institute Center for Precision
| | | |
Collapse
|
2
|
Dreher N, Layton TM, Parker BA, Shibley WP, Acerbi I, Wallace AM, Blair S, Pierce JP, Glantz S, Guydish J, Hiatt R, van 't Veer L, Esserman L. Abstract P4-10-03: Tobacco exposure and breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-10-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Smoking is a known risk factor for various types of cancer, and breast cancer patients who smoke are known to have higher breast cancer mortality. However, few studies have found an association between smoking and breast cancer incidence or tumor biology. The Athena Breast Health Network distributes an intake questionnaire at the UCSF and UCSD breast care centers which can be used to investigate links between tobacco exposure and the characteristics of incident breast cancer.
Methods: Intake questionnaires were distributed to all new patients at the UCSF and UCSD breast care centers from December 2012 to May 2018. Patients who completed the questionnaire with a known diagnosis of breast cancer were compared to those without in a case-control study. Breast cancer diagnoses were determined by ICD9 diagnosis codes from the patients' medical records. The association of smoking and breast cancer prevalence and biology was analyzed using generalized linear models and Fisher tests in R.
Results: Of the 7727 patients who completed the Athena intake questionnaire at UCSF and UCSD, 5499 consented to have their data used for research. A first analysis was conducted on 4175 UCSF patients alone: 2186 of the UCSF patients who had completed the questionnaire had a documented breast cancer diagnosis, vs 1989 with no known diagnosis at the time of this analysis. 1096 of the 4175 UCSF patients reported having ever smoked, including 73 who had accrued 30 or more pack years. Complete pathology data was available for 1120 cancer patients. Controlling for age, more patients with invasive breast cancer reported having ever smoked, with an odd's ratio (OR) of 2.32 (p = .0043). By including DCIS, the OR drops slightly to 2.26 (p = .0058). Taking alcohol consumption into account as a confounder lowered the OR to 2.19 (p = .0454). Overall, the risk of breast cancer increases with each additional pack year (OR = 1.08, p = .0211), independent of age. There are no significant differences in tumor biology for any smoking group.
Conclusions: A history of smoking is associated with an increased risk of developing breast cancer and is directly related to cumulative pack years exposure. This association should be further validated in cohort studies.
Citation Format: Dreher N, Layton TM, Parker BA, Shibley WP, Acerbi I, Wallace AM, Blair S, Pierce JP, Glantz S, Guydish J, Hiatt R, van 't Veer L, Esserman L, Athena Breast Health Network Investigators and Advocate Partners. Tobacco exposure and breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-10-03.
Collapse
Affiliation(s)
- N Dreher
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA
| | - TM Layton
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA
| | - BA Parker
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA
| | - WP Shibley
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA
| | - I Acerbi
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA
| | - AM Wallace
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA
| | - S Blair
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA
| | - JP Pierce
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA
| | - S Glantz
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA
| | - J Guydish
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA
| | - R Hiatt
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA
| | - L van 't Veer
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA
| | - L Esserman
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA
| | | |
Collapse
|
3
|
Hosseini A, Esserman LJ, Wallace AM, Au A, Mukhtar RA. Abstract P5-22-22: Breast tumor location in BRCA mutation carriers and implications for prevention. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p5-22-22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction:
Close to 65% of BRCA mutation carriers do not choose prophylactic mastectomy, despite their high breast cancer risk. Breast reduction mammoplasty is a surgical technique shown to reduce breast cancer risk and can be modified to target specific areas of the breast. We wondered if a majority of tumors in BRCA mutation carriers would be confined to one quadrant, allowing for the use of targeted cosmetic mammoplasty as a novel method of risk reduction.
Methods:
We reviewed imaging reports on 103 consecutive patients with BRCA mutations and invasive breast cancer, and categorized tumor location by quadrant. Tumors spanning >1 quadrant were classified as being in both. Bilateral cancers were counted separately. Categorical variables were compared with the chi-squaredtest.
Results:
Mean age at breast cancer diagnosis was 44 years with mean tumor size of 2.2 cm (0.1-7cm). 92% of tumors were invasive ductal carcinoma, 46% were hormone receptor positive, 10% Her2 positive, and 44% triple negative. 70% of the tumors were unicentric. Tumors were significantly more likely to be in the upper outer quadrant whether or not multicentric tumors were included in the analysis (p<0.00001). Her2 positive tumors were more likely to be multicentric than other subtypes (p=0.021).
Conclusions:
More than half of breast cancers in BRCA mutation carriers form in the upper outer quadrant, suggesting that removing this quadrant through breast reduction mammoplasty could significantly reduce breast cancer risk. For women who are not ready for prophylactic mastectomy, this data supports an intermediate risk reduction step instead of only offering surveillance.
Citation Format: Hosseini A, Esserman LJ, Wallace AM, Au A, Mukhtar RA. Breast tumor location in BRCA mutation carriers and implications for prevention [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-22-22.
Collapse
Affiliation(s)
- A Hosseini
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA
| | - LJ Esserman
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA
| | - AM Wallace
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA
| | - A Au
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA
| | - RA Mukhtar
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA
| |
Collapse
|
4
|
Yee D, Paoloni M, van't Veer L, Sanil A, Yau C, Forero A, Chien AJ, Wallace AM, Moulder S, Albain KS, Kaplan HG, Elias AD, Haley BB, Boughey JC, Kemmer KA, Korde LA, Isaacs C, Minton S, Nanda R, DeMichele A, Lang JE, Buxton MB, Hylton NM, Symmans WF, Lyandres J, Hogarth M, Perlmutter J, Esserman LJ, Berry DA. Abstract P6-11-04: The evaluation of ganitumab/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p6-11-04] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: I-SPY 2 is a multicenter, phase 2 trial using response-adaptive randomization within biomarker subtypes to evaluate novel agents when added to standard neoadjuvant therapy for women with high-risk stage II/III breast cancer - investigational agent(I) +paclitaxel(T) qwk, doxorubicin & cyclophosphamide(AC) q2-3 wk x 4 vs. T/AC (control arm). The primary endpoint is pathologic complete response (pCR) at surgery. The goal is to identify/graduate regimens that have ≥85% Bayesian predictive probability of success (statistical significance) in a 300-patient phase 3 neoadjuvant trial defined by hormone-receptor (HR) & HER2 status & MammaPrint (MP). Regimens may also leave the trial for futility (< 10% probability of success) or following accrual of maximum sample size (10%< probability of success <85%). We report the results for experimental arm Ganitumab, a type I insulin-like growth factor receptor (IGF1R) inhibitor. IGF1R inhibitors are known to induce insulin resistance and all patients assigned to Ganitumab received metformin.
Methods: Women with tumors ≥2.5cm were eligible for screening. MP low/HR+ and HER2+ tumors were ineligible for randomization. Hemoglobin A1C≥ 8.0% were ineligible. MRI scans (baseline, 3 cycles after start of therapy, at completion of weekly T and prior to surgery) were used in a longitudinal statistical model to improve the efficiency of adaptive randomization. Ganitumab was given at 12mg/kg q2 weeks and metformin at 850mg PO BID, while receiving ganitumab. Analysis was intention to treat with patients who switched to non-protocol therapy counted as non-pCRs. Ganitumab/metformin was open only to HER2- patients, and eligible for graduation in 3 of 10 pre-defined signatures: HER2-, HR+HER2- and HR-HER2-.
Results: Ganitumab/metformin did not meet the criteria for graduation in the 3 signatures tested. When the maximum sample size was reached, accrual to this arm stopped. Ganitumab/metformin was assigned to 106 patients; there were 128 controls. We report probabilities of superiority for Ganitumab/metformin over control and Bayesian predictive probabilities of success in a neoadjuvant phase 3 trial equally randomized between Ganitumab/metformin and control, for each of the 3 biomarker signatures, using the final pathological response data from all patients. Safety data will be presented.
SignatureEstimated pCR Rate (95% probability interval)Probability Ganitumab/ Metformin Is Superior to ControlPredictive Probability of Success in Phase 3 Ganitumab/ Metformin N = 106Control N = 128 All HER2-22% (13%-31%)16% (10%-23%)89%33%HR+/HER2-14% (4%-24%)12% (4%-19%)66%21%HR-/HER2-32% (17%-46%)21% (11%-32%)91%51%
Conclusion: The I-SPY 2 adaptive randomization study estimates the probability that investigational regimens will be successful in a phase 3 neoadjuvant trial. The value of I-SPY 2 is to give insight about the performance of an investigational agent's likelihood of achieving pCR. For Ganitumab/metformin, no subtype came close to the efficacy threshold of 85% likelihood of success in phase 3, and this regimen does not appear to impact upfront reduction of tumor burden. Our data do not support its continued development for the neoadjuvant treatment of breast cancer.
Citation Format: Yee D, Paoloni M, van't Veer L, Sanil A, Yau C, Forero A, Chien AJ, Wallace AM, Moulder S, Albain KS, Kaplan HG, Elias AD, Haley BB, Boughey JC, Kemmer KA, Korde LA, Isaacs C, Minton S, Nanda R, DeMichele A, Lang JE, Buxton MB, Hylton NM, Symmans WF, Lyandres J, Hogarth M, Perlmutter J, Esserman LJ, Berry DA. The evaluation of ganitumab/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-11-04.
Collapse
Affiliation(s)
- D Yee
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - M Paoloni
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - L van't Veer
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - A Sanil
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - C Yau
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - A Forero
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - AJ Chien
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - AM Wallace
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - S Moulder
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - KS Albain
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - HG Kaplan
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - AD Elias
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - BB Haley
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - JC Boughey
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - KA Kemmer
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - LA Korde
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - C Isaacs
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - S Minton
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - R Nanda
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - A DeMichele
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - JE Lang
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - MB Buxton
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - NM Hylton
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - WF Symmans
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - J Lyandres
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - M Hogarth
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - J Perlmutter
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - LJ Esserman
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| | - DA Berry
- University of Minnesota, Minneapolis, MN; QuantumLeap Healthcare Collaborative, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Berry Consultants, Austin, TX; University of Alabama at Birmingham, Birmingham, AL; University of California, San Diego, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Loyola University, Chicago, IL; Swedish Medical Center, Seattle, WA; University of Denver, Denver, CO; UT Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; University of Washington, Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; University of Arizona, AZ; University of California, Davis, Davis, CA; Gemini Group, Ann Arbor, MI
| |
Collapse
|
5
|
Forero A, Yee D, Buxton MB, Symmans WF, Chien AJ, Boughey JC, Elias AD, DeMichele A, Moulder S, Minton S, Kaplan HG, Albain KS, Wallace AM, Haley BB, Isaacs C, Korde LA, Nanda R, Lang JE, Kemmer KA, Hylton NM, Paoloni M, van't Veer L, Lyandres J, Perlmutter J, Hogarth M, Yau C, Sanil A, Berry DA, Esserman LJ. Abstract P6-11-02: Efficacy of Hsp90 inhibitor ganetespib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p6-11-02] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:Pathologic complete response(pCR) after neoadjuvant therapy is an established prognostic biomarker for high-risk breast cancer(BC). Improving pCR rates may identify new therapies that improve survival. I-SPY 2 uses response-adaptive randomization within biomarker subtypes to evaluate novel agents when added to standard neoadjuvant therapy for women with high-risk stage II/III breast cancer; the goal is to identify regimens that have ≥85% Bayesian predictive probability of success (statistical significance) in a 300-patient phase 3 neoadjuvant trial defined by hormone-receptor (HR), HER2 status and MammaPrint (MP). We report the results for Ganetespib, a selective inhibitor of Hsp90 that induces the degradation/deactivation of key drivers of tumor initiation, progression, angiogenesis, and metastasis.Ganetespib + taxanes previously have resulted in a superior therapeutic response compared to monotherapy in multiple solid tumor models including BC.
Methods:Women with tumors ≥2.5cm were eligible for screening and participation. MP low/HR+ tumors were ineligible for randomization. QTcF >470msec and HbA1C >8.0% were ineligible. MRI scans (baseline, +3 cycles, following weekly paclitaxel, T, and pre-surgery) were used in a longitudinal statistical model to improve the efficiency of adaptive randomization. Ganetespib was given with weekly T at 150 mg/m2 IV weekly (3 weeks on, 1 off). Patients were premedicated (dexamethasone 10mg and diphenhydramine HCl 25-50 mg, or therapeutic equivalents). Analysis was intention to treat with patients who switched to non-protocol therapy counted as non-pCRs. The Ganetespib regimen was open only to HER2- patients, and eligible for graduation in 3 of 10 pre-defined signatures: HER2-, HR+/HER2- and HR-/HER2-.
Results:Ganetespib did not meet the criteria for graduation in the 3 signatures tested. When the maximum sample size was reached, accrual stopped. Ganetespib was assigned to 93 patients; there were 140 controls. We report probabilities of superiority for Ganetespib over control and Bayesian predictive probabilities of success in a neoadjuvant phase 3 trial equally randomized between Ganetespib and control, for the 3 biomarker signatures, using the final pCR data from all patients. Safety data will be presented.
SignatureEstimated pCR Rate (95% probability interval)Probability Ganetespib Is Superior to ControlPredictive Probability of Ganetespib Success in a Phase 3 Trial Ganetespib N = 93Control N = 140 All HER2-26% (16%-37%)18% (8%-28%)91%47%HR+/HER2-15% (4%-27%)14% (4%-24%)60%19%HR-/HER2-38% (23%-53%)22% (9%-35%)96%72%
Conclusion:The I-SPY 2 adaptive randomization model efficiently evaluates investigational agents in the setting of neoadjuvant BC. The value of I-SPY 2 is that it provides insight as to the regimen's likelihood of success in a phase 3 neoadjuvant study. Although no signature reached the efficacy threshold of 85% likelihood of success in phase 3, we observed the most impact in HR-/HER2- patients, with a 16% improvement in pCR rate. While our data do not support the continued development of Ganetespib alone for neoadjuvant BC, combinations with Ganetespib, which could potentiate its effect, may be worth pursuing in I-SPY 2 or similar trials.
Citation Format: Forero A, Yee D, Buxton MB, Symmans WF, Chien AJ, Boughey JC, Elias AD, DeMichele A, Moulder S, Minton S, Kaplan HG, Albain KS, Wallace AM, Haley BB, Isaacs C, Korde LA, Nanda R, Lang JE, Kemmer KA, Hylton NM, Paoloni M, van't Veer L, Lyandres J, Perlmutter J, Hogarth M, Yau C, Sanil A, Berry DA, Esserman LJ. Efficacy of Hsp90 inhibitor ganetespib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-11-02.
Collapse
Affiliation(s)
- A Forero
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - D Yee
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - MB Buxton
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - WF Symmans
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - AJ Chien
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - JC Boughey
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - AD Elias
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - A DeMichele
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - S Moulder
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - S Minton
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - HG Kaplan
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - KS Albain
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - AM Wallace
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - BB Haley
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - C Isaacs
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - LA Korde
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - R Nanda
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - JE Lang
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - KA Kemmer
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - NM Hylton
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - M Paoloni
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - L van't Veer
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - J Lyandres
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - J Perlmutter
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - M Hogarth
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - C Yau
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - A Sanil
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - DA Berry
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| | - LJ Esserman
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; University of California, San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; University of Denver, Denver, CO; University of Pennsylvania, Philadelphia, PA; Moffitt Cancer Center, Tampa, FL; Swedish Medical Center, Seattle, WA; Loyola University, Chicago, IL; University of California, San Diego, San Diego, CA; UT Southwestern Medical Center, Dallas, TX; Georgetown Lomdbardi Comprehensive Cancer Center, Washington, DC; University of Washington, Seattle, WA; University of Chicago, Chicago, IL; University of Arizona, AZ; Oregon Health and Science University, Portland, OR; QuantumLeap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Arbor, MI; University of California, Davis, Davis, CA; Berry Consultants, Austin, TX
| |
Collapse
|
6
|
Schoenbrunner AR, Fero KE, Boero IJ, Matsuno R, Kronstadt N, Lance S, Reid C, Wallace AM, Gosman AA, Murphy JD. Abstract P3-14-02: Post mastectomy breast reconstruction in elderly women: Complications and the impact of individual surgeons. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p3-14-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose/Objective
In the United States over 40% of incident breast cancer diagnoses are in women over 65 years of age. Effective breast cancer treatments allow elderly patients to live long, healthy lives; questions regarding long-term quality of life are increasingly important. In women over 65, post-mastectomy breast reconstruction (PMBR) is uncommon with reported rates of 6-30%. The goal of this study is to report complication rates in elderly PMBR patients and to evaluate the impact of individual surgeons on PMBR in elderly patients.
Material/methods
We identified 19,417 Medicare beneficiaries diagnosed with localized breast cancer between 2005 and 2011 who underwent mastectomy. Medicare claims were used to identify PMBR, post-operative complications after PMBR (within 30 days of surgery), and long-term complications related to reconstruction (within three years following surgery). Mastectomy surgeon was identified from Medicare claims with surgeon characteristics identified through linkage to the American Medical Association (AMA) Masterfile.
Multi-level, multivariable logistic models clustered by surgeon and geographic area were used to determine the impact of surgeons on the likelihood of reconstruction. The intraclass correlation coefficient (ICC) and median odds ratio (MOR) were used to describe the relative impact of the individual surgeon. The ICC estimates the proportion of variability explained by the surgeon on PMBR rates. The MOR quantifies the likelihood of a patient having a different PMBR outcome if the patient were to change surgeons (or geographic area); it is directly comparable to odds ratios. Odds ratios (OR) were used to describe the impact of fixed demographic and clinical covariates.
Results
Among the entire cohort, 1,234 (6.4%) patients underwent PMBR. The post-operative complication rate was 8.4% and the long-term complication rate was 19.9%. Eighteen percent of the variability in PMBR use was attributed to the individual surgeon (ICC 0.181). The MOR for surgeon was found to be 1.85 (95% CI [1.70,1.99]), indicating that a patient had an 85% chance of having a different outcome (receiving or not receiving PMBR) if the patient saw a different mastectomy surgeon. The MOR for geographic area indicated that a patient had a 32% chance of having a different outcome if the patient saw a surgeon in a different geographic area (1.32, 95% CI [1.17, 1.47]). Patients who were Asian, single, older, of lower socioeconomic status, and underwent radiation therapy were less likely to undergo PMBR. Patients who had pre-operative MRI or received chemotherapy were more likely to undergo PMBR. Patients who were treated by female surgeons or plastic surgeons were significantly more likely to undergo PMBR. Overall, the individual surgeon was the most predictive of PMBR, except for the use of pre-operative MRI and mastectomy surgeon's specialty being plastic surgery.
Conclusion
A small minority of older women undergo PMBR despite having low post-operative and long-term complication rates. The individual surgeon and geographic area significantly influences whether older breast cancer patients will undergo PMBR. Future research should focus on surgeon characteristics that may influence a patient's decision to undergo PMBR.
Citation Format: Schoenbrunner AR, Fero KE, Boero IJ, Matsuno R, Kronstadt N, Lance S, Reid C, Wallace AM, Gosman AA, Murphy JD. Post mastectomy breast reconstruction in elderly women: Complications and the impact of individual surgeons [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P3-14-02.
Collapse
Affiliation(s)
- AR Schoenbrunner
- University of California, San Diego School of Medicine; University of California, San Diego
| | - KE Fero
- University of California, San Diego School of Medicine; University of California, San Diego
| | - IJ Boero
- University of California, San Diego School of Medicine; University of California, San Diego
| | - R Matsuno
- University of California, San Diego School of Medicine; University of California, San Diego
| | - N Kronstadt
- University of California, San Diego School of Medicine; University of California, San Diego
| | - S Lance
- University of California, San Diego School of Medicine; University of California, San Diego
| | - C Reid
- University of California, San Diego School of Medicine; University of California, San Diego
| | - AM Wallace
- University of California, San Diego School of Medicine; University of California, San Diego
| | - AA Gosman
- University of California, San Diego School of Medicine; University of California, San Diego
| | - JD Murphy
- University of California, San Diego School of Medicine; University of California, San Diego
| |
Collapse
|
7
|
Clifton S, Macdowall W, Copas AJ, Tanton C, Keevil BG, Lee DM, Mitchell KR, Field N, Sonnenberg P, Bancroft J, Mercer CH, Wallace AM, Johnson AM, Wellings K, Wu FCW. Salivary Testosterone Levels and Health Status in Men and Women in the British General Population: Findings from the Third National Survey of Sexual Attitudes and Lifestyles (Natsal-3). J Clin Endocrinol Metab 2016; 101:3939-3951. [PMID: 27552539 PMCID: PMC5095233 DOI: 10.1210/jc.2016-1669] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
CONTEXT Salivary T (Sal-T) measurement by liquid chromatography-tandem mass spectroscopy resents the opportunity to examine health correlates of Sal-T in a large-scale population survey. OBJECTIVE This study sought to examine associations between Sal-T and health-related factors in men and women age 18-74 years. DESIGN AND SETTING Morning saliva samples were obtained from participants in a cross-sectional probability-sample survey of the general British population (Natsal-3). Self-reported health and lifestyle questions were administered as part of a wider sexual health interview. PARTICIPANTS Study participants included 1599 men and 2123 women. METHODS Sal-T was measured using liquid chromatography-tandem mass spectroscopy. Linear regression was used to examine associations between health factors and mean Sal-T. RESULTS In men, mean Sal-T was associated with a range of health factors after age adjustment, and showed a strong independent negative association with body mass index (BMI) in multivariable analysis. Men reporting cardiovascular disease or currently taking medication for depression had lower age-adjusted Sal-T, although there was no association with cardiovascular disease after adjustment for BMI. The decline in Sal-T with increasing age remained after adjustment for health-related factors. In women, Sal-T declined with increasing age; however, there were no age-independent associations with health-related factors or specific heath conditions with the exception of higher Sal-T in smokers. CONCLUSIONS Sal-T levels were associated, independently of age, with a range of self-reported health markers, particularly BMI, in men but not women. The findings support the view that there is an age-related decline in Sal-T in men and women, which cannot be explained by an increase in ill health. Our results demonstrate the potential of Sal-T as a convenient measure of tissue androgen exposure for population research.
Collapse
Affiliation(s)
- S Clifton
- Research Department of Infection and Population Health (S.C., A.J.C., C.T., N.F., P.S., C.H.M., A.M.J.), University College London, London WC1E 6BT, United Kingdom; Department of Social and Environmental Health Research (W.M., K.R.M., K.W.), London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom; Department of Clinical Biochemistry (B.G.K.), University Hospital S Manchester, Manchester M13 9WL, United Kingdom; Cathie Marsh Institute for Social Research, School of Social Sciences (D.M.L.), The University of Manchester, Manchester M13 9WL, United Kingdom; MRC/CSO Social and Public Health Sciences Unit (K.R.M.), University of Glasgow, Glasgow G12 8QQ, United Kingdom; Kinsey Institute (J.B.), Indiana University, Bloomington, Indiana 47405; Department of Clinical Biochemistry (A.M.W.), Royal Infirmary, Glasgow G4 0SF, United Kingdom; and Andrology Research Unit (F.C.W.W.), Manchester Centre of Endocrinology and Diabetes, Manchester Academic Health Science Centre, The University of Manchester, Manchester M13 9PL, United Kingdom
| | - W Macdowall
- Research Department of Infection and Population Health (S.C., A.J.C., C.T., N.F., P.S., C.H.M., A.M.J.), University College London, London WC1E 6BT, United Kingdom; Department of Social and Environmental Health Research (W.M., K.R.M., K.W.), London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom; Department of Clinical Biochemistry (B.G.K.), University Hospital S Manchester, Manchester M13 9WL, United Kingdom; Cathie Marsh Institute for Social Research, School of Social Sciences (D.M.L.), The University of Manchester, Manchester M13 9WL, United Kingdom; MRC/CSO Social and Public Health Sciences Unit (K.R.M.), University of Glasgow, Glasgow G12 8QQ, United Kingdom; Kinsey Institute (J.B.), Indiana University, Bloomington, Indiana 47405; Department of Clinical Biochemistry (A.M.W.), Royal Infirmary, Glasgow G4 0SF, United Kingdom; and Andrology Research Unit (F.C.W.W.), Manchester Centre of Endocrinology and Diabetes, Manchester Academic Health Science Centre, The University of Manchester, Manchester M13 9PL, United Kingdom
| | - A J Copas
- Research Department of Infection and Population Health (S.C., A.J.C., C.T., N.F., P.S., C.H.M., A.M.J.), University College London, London WC1E 6BT, United Kingdom; Department of Social and Environmental Health Research (W.M., K.R.M., K.W.), London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom; Department of Clinical Biochemistry (B.G.K.), University Hospital S Manchester, Manchester M13 9WL, United Kingdom; Cathie Marsh Institute for Social Research, School of Social Sciences (D.M.L.), The University of Manchester, Manchester M13 9WL, United Kingdom; MRC/CSO Social and Public Health Sciences Unit (K.R.M.), University of Glasgow, Glasgow G12 8QQ, United Kingdom; Kinsey Institute (J.B.), Indiana University, Bloomington, Indiana 47405; Department of Clinical Biochemistry (A.M.W.), Royal Infirmary, Glasgow G4 0SF, United Kingdom; and Andrology Research Unit (F.C.W.W.), Manchester Centre of Endocrinology and Diabetes, Manchester Academic Health Science Centre, The University of Manchester, Manchester M13 9PL, United Kingdom
| | - C Tanton
- Research Department of Infection and Population Health (S.C., A.J.C., C.T., N.F., P.S., C.H.M., A.M.J.), University College London, London WC1E 6BT, United Kingdom; Department of Social and Environmental Health Research (W.M., K.R.M., K.W.), London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom; Department of Clinical Biochemistry (B.G.K.), University Hospital S Manchester, Manchester M13 9WL, United Kingdom; Cathie Marsh Institute for Social Research, School of Social Sciences (D.M.L.), The University of Manchester, Manchester M13 9WL, United Kingdom; MRC/CSO Social and Public Health Sciences Unit (K.R.M.), University of Glasgow, Glasgow G12 8QQ, United Kingdom; Kinsey Institute (J.B.), Indiana University, Bloomington, Indiana 47405; Department of Clinical Biochemistry (A.M.W.), Royal Infirmary, Glasgow G4 0SF, United Kingdom; and Andrology Research Unit (F.C.W.W.), Manchester Centre of Endocrinology and Diabetes, Manchester Academic Health Science Centre, The University of Manchester, Manchester M13 9PL, United Kingdom
| | - B G Keevil
- Research Department of Infection and Population Health (S.C., A.J.C., C.T., N.F., P.S., C.H.M., A.M.J.), University College London, London WC1E 6BT, United Kingdom; Department of Social and Environmental Health Research (W.M., K.R.M., K.W.), London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom; Department of Clinical Biochemistry (B.G.K.), University Hospital S Manchester, Manchester M13 9WL, United Kingdom; Cathie Marsh Institute for Social Research, School of Social Sciences (D.M.L.), The University of Manchester, Manchester M13 9WL, United Kingdom; MRC/CSO Social and Public Health Sciences Unit (K.R.M.), University of Glasgow, Glasgow G12 8QQ, United Kingdom; Kinsey Institute (J.B.), Indiana University, Bloomington, Indiana 47405; Department of Clinical Biochemistry (A.M.W.), Royal Infirmary, Glasgow G4 0SF, United Kingdom; and Andrology Research Unit (F.C.W.W.), Manchester Centre of Endocrinology and Diabetes, Manchester Academic Health Science Centre, The University of Manchester, Manchester M13 9PL, United Kingdom
| | - D M Lee
- Research Department of Infection and Population Health (S.C., A.J.C., C.T., N.F., P.S., C.H.M., A.M.J.), University College London, London WC1E 6BT, United Kingdom; Department of Social and Environmental Health Research (W.M., K.R.M., K.W.), London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom; Department of Clinical Biochemistry (B.G.K.), University Hospital S Manchester, Manchester M13 9WL, United Kingdom; Cathie Marsh Institute for Social Research, School of Social Sciences (D.M.L.), The University of Manchester, Manchester M13 9WL, United Kingdom; MRC/CSO Social and Public Health Sciences Unit (K.R.M.), University of Glasgow, Glasgow G12 8QQ, United Kingdom; Kinsey Institute (J.B.), Indiana University, Bloomington, Indiana 47405; Department of Clinical Biochemistry (A.M.W.), Royal Infirmary, Glasgow G4 0SF, United Kingdom; and Andrology Research Unit (F.C.W.W.), Manchester Centre of Endocrinology and Diabetes, Manchester Academic Health Science Centre, The University of Manchester, Manchester M13 9PL, United Kingdom
| | - K R Mitchell
- Research Department of Infection and Population Health (S.C., A.J.C., C.T., N.F., P.S., C.H.M., A.M.J.), University College London, London WC1E 6BT, United Kingdom; Department of Social and Environmental Health Research (W.M., K.R.M., K.W.), London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom; Department of Clinical Biochemistry (B.G.K.), University Hospital S Manchester, Manchester M13 9WL, United Kingdom; Cathie Marsh Institute for Social Research, School of Social Sciences (D.M.L.), The University of Manchester, Manchester M13 9WL, United Kingdom; MRC/CSO Social and Public Health Sciences Unit (K.R.M.), University of Glasgow, Glasgow G12 8QQ, United Kingdom; Kinsey Institute (J.B.), Indiana University, Bloomington, Indiana 47405; Department of Clinical Biochemistry (A.M.W.), Royal Infirmary, Glasgow G4 0SF, United Kingdom; and Andrology Research Unit (F.C.W.W.), Manchester Centre of Endocrinology and Diabetes, Manchester Academic Health Science Centre, The University of Manchester, Manchester M13 9PL, United Kingdom
| | - N Field
- Research Department of Infection and Population Health (S.C., A.J.C., C.T., N.F., P.S., C.H.M., A.M.J.), University College London, London WC1E 6BT, United Kingdom; Department of Social and Environmental Health Research (W.M., K.R.M., K.W.), London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom; Department of Clinical Biochemistry (B.G.K.), University Hospital S Manchester, Manchester M13 9WL, United Kingdom; Cathie Marsh Institute for Social Research, School of Social Sciences (D.M.L.), The University of Manchester, Manchester M13 9WL, United Kingdom; MRC/CSO Social and Public Health Sciences Unit (K.R.M.), University of Glasgow, Glasgow G12 8QQ, United Kingdom; Kinsey Institute (J.B.), Indiana University, Bloomington, Indiana 47405; Department of Clinical Biochemistry (A.M.W.), Royal Infirmary, Glasgow G4 0SF, United Kingdom; and Andrology Research Unit (F.C.W.W.), Manchester Centre of Endocrinology and Diabetes, Manchester Academic Health Science Centre, The University of Manchester, Manchester M13 9PL, United Kingdom
| | - P Sonnenberg
- Research Department of Infection and Population Health (S.C., A.J.C., C.T., N.F., P.S., C.H.M., A.M.J.), University College London, London WC1E 6BT, United Kingdom; Department of Social and Environmental Health Research (W.M., K.R.M., K.W.), London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom; Department of Clinical Biochemistry (B.G.K.), University Hospital S Manchester, Manchester M13 9WL, United Kingdom; Cathie Marsh Institute for Social Research, School of Social Sciences (D.M.L.), The University of Manchester, Manchester M13 9WL, United Kingdom; MRC/CSO Social and Public Health Sciences Unit (K.R.M.), University of Glasgow, Glasgow G12 8QQ, United Kingdom; Kinsey Institute (J.B.), Indiana University, Bloomington, Indiana 47405; Department of Clinical Biochemistry (A.M.W.), Royal Infirmary, Glasgow G4 0SF, United Kingdom; and Andrology Research Unit (F.C.W.W.), Manchester Centre of Endocrinology and Diabetes, Manchester Academic Health Science Centre, The University of Manchester, Manchester M13 9PL, United Kingdom
| | - J Bancroft
- Research Department of Infection and Population Health (S.C., A.J.C., C.T., N.F., P.S., C.H.M., A.M.J.), University College London, London WC1E 6BT, United Kingdom; Department of Social and Environmental Health Research (W.M., K.R.M., K.W.), London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom; Department of Clinical Biochemistry (B.G.K.), University Hospital S Manchester, Manchester M13 9WL, United Kingdom; Cathie Marsh Institute for Social Research, School of Social Sciences (D.M.L.), The University of Manchester, Manchester M13 9WL, United Kingdom; MRC/CSO Social and Public Health Sciences Unit (K.R.M.), University of Glasgow, Glasgow G12 8QQ, United Kingdom; Kinsey Institute (J.B.), Indiana University, Bloomington, Indiana 47405; Department of Clinical Biochemistry (A.M.W.), Royal Infirmary, Glasgow G4 0SF, United Kingdom; and Andrology Research Unit (F.C.W.W.), Manchester Centre of Endocrinology and Diabetes, Manchester Academic Health Science Centre, The University of Manchester, Manchester M13 9PL, United Kingdom
| | - C H Mercer
- Research Department of Infection and Population Health (S.C., A.J.C., C.T., N.F., P.S., C.H.M., A.M.J.), University College London, London WC1E 6BT, United Kingdom; Department of Social and Environmental Health Research (W.M., K.R.M., K.W.), London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom; Department of Clinical Biochemistry (B.G.K.), University Hospital S Manchester, Manchester M13 9WL, United Kingdom; Cathie Marsh Institute for Social Research, School of Social Sciences (D.M.L.), The University of Manchester, Manchester M13 9WL, United Kingdom; MRC/CSO Social and Public Health Sciences Unit (K.R.M.), University of Glasgow, Glasgow G12 8QQ, United Kingdom; Kinsey Institute (J.B.), Indiana University, Bloomington, Indiana 47405; Department of Clinical Biochemistry (A.M.W.), Royal Infirmary, Glasgow G4 0SF, United Kingdom; and Andrology Research Unit (F.C.W.W.), Manchester Centre of Endocrinology and Diabetes, Manchester Academic Health Science Centre, The University of Manchester, Manchester M13 9PL, United Kingdom
| | - A M Wallace
- Research Department of Infection and Population Health (S.C., A.J.C., C.T., N.F., P.S., C.H.M., A.M.J.), University College London, London WC1E 6BT, United Kingdom; Department of Social and Environmental Health Research (W.M., K.R.M., K.W.), London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom; Department of Clinical Biochemistry (B.G.K.), University Hospital S Manchester, Manchester M13 9WL, United Kingdom; Cathie Marsh Institute for Social Research, School of Social Sciences (D.M.L.), The University of Manchester, Manchester M13 9WL, United Kingdom; MRC/CSO Social and Public Health Sciences Unit (K.R.M.), University of Glasgow, Glasgow G12 8QQ, United Kingdom; Kinsey Institute (J.B.), Indiana University, Bloomington, Indiana 47405; Department of Clinical Biochemistry (A.M.W.), Royal Infirmary, Glasgow G4 0SF, United Kingdom; and Andrology Research Unit (F.C.W.W.), Manchester Centre of Endocrinology and Diabetes, Manchester Academic Health Science Centre, The University of Manchester, Manchester M13 9PL, United Kingdom
| | - A M Johnson
- Research Department of Infection and Population Health (S.C., A.J.C., C.T., N.F., P.S., C.H.M., A.M.J.), University College London, London WC1E 6BT, United Kingdom; Department of Social and Environmental Health Research (W.M., K.R.M., K.W.), London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom; Department of Clinical Biochemistry (B.G.K.), University Hospital S Manchester, Manchester M13 9WL, United Kingdom; Cathie Marsh Institute for Social Research, School of Social Sciences (D.M.L.), The University of Manchester, Manchester M13 9WL, United Kingdom; MRC/CSO Social and Public Health Sciences Unit (K.R.M.), University of Glasgow, Glasgow G12 8QQ, United Kingdom; Kinsey Institute (J.B.), Indiana University, Bloomington, Indiana 47405; Department of Clinical Biochemistry (A.M.W.), Royal Infirmary, Glasgow G4 0SF, United Kingdom; and Andrology Research Unit (F.C.W.W.), Manchester Centre of Endocrinology and Diabetes, Manchester Academic Health Science Centre, The University of Manchester, Manchester M13 9PL, United Kingdom
| | - K Wellings
- Research Department of Infection and Population Health (S.C., A.J.C., C.T., N.F., P.S., C.H.M., A.M.J.), University College London, London WC1E 6BT, United Kingdom; Department of Social and Environmental Health Research (W.M., K.R.M., K.W.), London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom; Department of Clinical Biochemistry (B.G.K.), University Hospital S Manchester, Manchester M13 9WL, United Kingdom; Cathie Marsh Institute for Social Research, School of Social Sciences (D.M.L.), The University of Manchester, Manchester M13 9WL, United Kingdom; MRC/CSO Social and Public Health Sciences Unit (K.R.M.), University of Glasgow, Glasgow G12 8QQ, United Kingdom; Kinsey Institute (J.B.), Indiana University, Bloomington, Indiana 47405; Department of Clinical Biochemistry (A.M.W.), Royal Infirmary, Glasgow G4 0SF, United Kingdom; and Andrology Research Unit (F.C.W.W.), Manchester Centre of Endocrinology and Diabetes, Manchester Academic Health Science Centre, The University of Manchester, Manchester M13 9PL, United Kingdom
| | - F C W Wu
- Research Department of Infection and Population Health (S.C., A.J.C., C.T., N.F., P.S., C.H.M., A.M.J.), University College London, London WC1E 6BT, United Kingdom; Department of Social and Environmental Health Research (W.M., K.R.M., K.W.), London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom; Department of Clinical Biochemistry (B.G.K.), University Hospital S Manchester, Manchester M13 9WL, United Kingdom; Cathie Marsh Institute for Social Research, School of Social Sciences (D.M.L.), The University of Manchester, Manchester M13 9WL, United Kingdom; MRC/CSO Social and Public Health Sciences Unit (K.R.M.), University of Glasgow, Glasgow G12 8QQ, United Kingdom; Kinsey Institute (J.B.), Indiana University, Bloomington, Indiana 47405; Department of Clinical Biochemistry (A.M.W.), Royal Infirmary, Glasgow G4 0SF, United Kingdom; and Andrology Research Unit (F.C.W.W.), Manchester Centre of Endocrinology and Diabetes, Manchester Academic Health Science Centre, The University of Manchester, Manchester M13 9PL, United Kingdom
| |
Collapse
|
8
|
Abstract
Background: The short Synacthen test (SST) is the most commonly used test for the assessment of adrenal suppression. We investigated the potential of a simpler and more cost-effective procedure [morning salivary cortisol (MSC)] as an outpatient screening tool to detect adrenal suppression in patients using topical intranasal corticosteroids for rhinosinusitis. Method: Forty-eight patients who were using topical corticosteroids underwent adrenal function assessment by way of SST and MSC measurement. Results: Sixteen of the 48 patients had impaired MSCs. Of these 16 patients, 15 had an impaired SST (sensitivity 100%) and one had a normal SST. All patients with normal MSCs also had normal SSTs (specificity 97%). Conclusion: The morning salivary cortisol measurement is a useful screening tool for adrenal suppression in this setting.
Collapse
Affiliation(s)
- Rajan S Patel
- Department of Otolaryngology, North Glasgow Hospitals University, NHS Trust, Glasgow, UK.
| | | | | | | | | |
Collapse
|
9
|
Affiliation(s)
- A M Wallace
- Institute of Biochemistry, Royal Infirmary, Glasgow G4 0SF, UK
| | - G H Beastall
- Institute of Biochemistry, Royal Infirmary, Glasgow G4 0SF, UK
| |
Collapse
|
10
|
Unkart JT, Wallace AM. Abstract P3-01-05: The use of Tc-99 tilmanocept in sentinel lymph node biopsy after neoadjuvant chemotherapy in clinically node-negative patients with breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p3-01-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Neoadjuvant chemotherapy (NAT) has been shown to induce fibrosis and inflammation that alters lymphatic drainage of axillary lymph nodes in breast cancer. Technetium- 99 Tilmanocept (TcTM), a CD206-macrophage receptor targeted radiopharmaceutical, is a small agent with recent FDA-approval for lymphatic mapping. No prior studies have investigated the use of TcTM in the neoadjuvant setting. The aim of this study was to compare the identification rate, node-positivity rate, and number of total nodes evaluated in sentinel lymph node (SLN) biopsy with TcTM and vital blue dye (VBD) in clinically node-negative patients receiving NAT vs. initial surgery.
Methods: A retrospective review was conducted on patients undergoing SLN biopsy with TcTM and VBD from May 2013- May 2015 at UCSD. Patients with a history of prior SLN biopsy or axillary lymph node dissection were excluded. Patients undergoing neoadjuvant chemotherapy or receiving > 3 months of neoadjuvant endocrine therapy were grouped and compared to patients undergoing initial surgical treatment. The SLN identification and node-positivity rates were compared with the X2 test. To compare the number of SLNs evaluated between groups, a zero-truncated negative binomial (ZTNB) count model was constructed to assess the effect of NAT and other covariates on the SLN count. Covariates included age, body mass index (BMI), gender, surgeon, mastectomy vs. lumpectomy, node positivity, pathologist, T-stage, and receptor status. A p-value < 0.05 was used for statistical significance.
Results: Of the 417 total SLN cases identified, 72 (17.2%) cases were in patients who had received NAT (61- chemo, 11- endocrine). The SLN identification rate was 100% in both groups (p= 1.0). Overall, there were 68 (16.3%) cases of SLN-positivity, 14 (19.4%) in the NAT group versus 54 (15.7%) in the non-NAT group (p= 0.54). The median number of identified nodes was 3 in both groups. In the ZTNB count model, age, surgeon and evaluating pathologist were significant predictors of the total number of SLN evaluated. The use of NAT did not significantly affect the number SLNs evaluated. Incident rate ratios, confidence intervals and p-values are reported in the attached table.
Sentinel Lymph Node Count ModelVariabeIRR95% CI LL95% CI ULp-valueAge per 5 years0.960.930.990.03Surgeon #21.231.051.450.01NAT1.140.921.410.22Pathologist #20.720.570.900.005Pathologist #31.010.841.220.90Pathologist #40.930.661.320.70IRR: incident rate ratio, NAT: neoadjuvant chemoendocrine therapy, CI: confidence interval, LL: lower limit, UL: upper limit
Discussion: Prior studies have indicated that NAT may induce fibrosis and inflammation that may obscure lymphatic mapping procedures. For SLN biopsy with TcTM in VBD in our study, the use of NAT did not change the identification rate or node-positivity rate. Additionally, when controlling for covariates, the use of NAT did not change the total number of SLNs evaluated. While NAT might induce fibrosis and inflammation, SLN biopsy with TcTM and VBD is technically successful in clinically node-negative patients undergoing neoadjuvant chemotherapy.
Citation Format: Unkart JT, Wallace AM. The use of Tc-99 tilmanocept in sentinel lymph node biopsy after neoadjuvant chemotherapy in clinically node-negative patients with breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-01-05.
Collapse
|
11
|
Wasik SM, Wallace AM. Combined preputial advancement and phallopexy as a revision technique for treating paraphimosis in a dog. Aust Vet J 2014; 92:433-6. [DOI: 10.1111/avj.12252] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/03/2014] [Indexed: 11/30/2022]
Affiliation(s)
- SM Wasik
- University of Melbourne Veterinary Clinic and Hospital; Werribee Victoria Australia
| | - AM Wallace
- University of Melbourne Veterinary Clinic and Hospital; Werribee Victoria Australia
| |
Collapse
|
12
|
Burton NJ, Ellis JR, Burton KJ, Wallace AM, Wallace AR, Colborne GR. An ex vivo investigation of the effect of the TATE canine elbow arthroplasty system on kinematics of the elbow. J Small Anim Pract 2013; 54:240-7. [PMID: 23560883 DOI: 10.1111/jsap.12060] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
OBJECTIVE To devise a kinematic technique to objectively ascertain the location and orientation of the centre of rotation of the canine elbow and to compare this axis following arthroplasty with the first generation TATE™ prosthesis in an ex vivo model. METHODS Five pairs of cadaveric forelimbs were obtained and proximal limb soft tissues removed. Pin-mounted reflective markers were applied to the humerus and ulna. Limbs were mounted on a frame and six trials of the elbow manually cycled through its sagittal range of motion captured using 4 Qualisys cameras at 120 Hz. Radiography was performed to identify marker position. TATE™ cartridges were implanted and kinematic analysis repeated. Kinematic data were imported into custom software and the three-dimensional joint centre of rotation defined using a closed-form solution for absolute orientation. Paired t tests were performed to determine if the centre of rotation of the elbow differed significantly (P<0·05) pre- and postoperatively and between left and right limbs. RESULTS There was no significant difference in three-dimensional orientation of the elbow axis between pre and postoperative measurements or between left and right limbs. CLINICAL SIGNIFICANCE A critical factor in obtaining a successful functional outcome following elbow arthroplasty in humans is accurate reconstruction of the anatomic centre of rotation. The first generation TATE canine elbow arthroplasty cartridge and its instrumentation accurately reconstructed the anatomic centre of rotation in 8 of the 10 elbows assessed in this ex vivo model.
Collapse
Affiliation(s)
- N J Burton
- Langford Veterinary Services, University of Bristol, Langford, N. Somerset, BS40 5DU, UK
| | | | | | | | | | | |
Collapse
|
13
|
Saba SC, Shaterian A, Tokin C, Dobke MK, Wallace AM. The pedicled myocutaneous flap as a choice reconstructive technique for immediate adjuvant brachytherapy in sarcoma treatment. ACTA ACUST UNITED AC 2013; 19:e491-5. [PMID: 23300372 DOI: 10.3747/co.19.1141] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
Successful treatment of soft-tissue sarcomas is highly dependent on total tumour resection coupled with adjuvant radiation therapy to achieve local control and decrease recurrence. Reconstruction of soft-tissue defects after resection aims to cover vital structures, while providing enough stable tissue to withstand adjuvant brachytherapy treatment. In the present study, pedicled myocutaneous flaps were used as a vital adjunct in the treatment of soft-tissue sarcoma, and our experience with 2 such patients is described. The flaps served to reconstruct large three-dimensional defects while providing stable coverage over brachytherapy hardware to allow for delivery of radiation in the immediate postoperative period. Pedicled locoregional myocutaneous flaps provide a safe, easy, and reliable reconstructive technique in the treatment of soft-tissue sarcoma.
Collapse
Affiliation(s)
- S C Saba
- Department of Surgery, Division of Plastic and Reconstructive Surgery, University of California-San Diego, CA, U.S.A
| | | | | | | | | |
Collapse
|
14
|
Schwab RB, Bao L, Pu M, Crain B, Dai Y, Nazareth LV, Matsui H, Wallace AM, Hasteh F, Harismendy O, Frazer KA, Parker BA, Messer K. Abstract P2-06-01: Breast-to-breast metastasis can cause hormone-receptor positive/triple negative bilateral synchronous tumors. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p2-06-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Prior work suggests that synchronous bilateral breast cancers may be clonal, with one tumor a metastasis, although prior techniques lacked resolution to prove this relationship. We used deep whole exome and shallow whole genome sequencing to compare bilateral tumors in two cases. In both cases, tumors were invasive and node negative with one tumor ER+/PR+/HER2− (HR+) lobular and the other triple negative (TN) ductal. Case 1 is a 75-year-old African American woman and Case 2 a 70-year-old white woman. With 44 and 12 months of follow up, respectively, neither patient has recurred.
Methods: Agilent SureSelect All Exon 50Mb Target Enrichment Kits were used for exome capture. Paired-end sequencing was performed with 200 base pair reads on the Illumina HiSeq 2000. Sequencing depth was targeted to cover 80% of the genome at 100x for three tumors with 70% cellularity, 200x for one tumor with 40% cellularity and 30x for germline. Tumor and germline exome results were compared to identify high confidence somatic single nucleotide variants (HC SNV). HC SNV's were called using GATK and stringent custom filtering to avoid false positives resulting from unrecognized germline single nucleotide polymorphisms. For each tumor pair, we define a clonality likelihood score (CLS) as the ratio of the number of HC SNV called at the same site and with the same alternate base in both tumors, to the total number of sites with an HC SNV called in either tumor. For comparison we analyzed the called SNV data from The Cancer Genome Atlas (TCGA) for exome sequenced HR+ or TN breast cancers.
Results: In Case 1, of 102 HC SNVs called in either tumor, 82 were shared, for a CLS of 80.3%. Additionally, 11 shared SNVs were synonymous, consistent with clonality. Lastly the non-shared HC SNVs were asymmetrically found in the TN tumor, consistent with clonal evolution during metastasis. Copy number analysis (CNA) showed Case 1 to have a deletion in 6q, including the ESR1 gene, unique to the TN tumor.
To assess significance of the CLS, we found three primary/metastatic clonal pairs in the TCGA to serve as positive controls. To serve as negative controls, from 357 ER+ and 46 TN primary TCGA tumors, we formed a total of 16,422 independent ER+/TN pairs. For the 3 clonal TCGA pairs, the CLS values were 39.3%, 58.5% and 60.0%. Most of the independent TCGA pairs had a CLS of zero (98.5%), with a maximum CLS of 2.8%. As the CLS for Case 1 lies above maximum observed CLS among 16,422 independent tumor pairs, we reject the hypothesis that this tumor pair is independent, at p < 0.0001. For Case 2, of 222 HC SNV sites, 5 were shared for a CLS of 2.3%, consistent with independence.
Conclusion: Somatic single nucleotide mutations identified by exome sequencing found that the two tumors in Case 1 share >80% of SNVs, consistent with clonal evolution of metastasis. The two tumors from Case 2 have few shared SNVs, consistent with independent origin. CNA results were consistent. This is the first clonality analysis reported from deep sequencing of phenotypically discordant synchronous bilateral breast cancers, and demonstrates that next-generation sequencing can distinguish clonal from independent tumor pairs with high confidence.
Funding: The Breast Cancer Research Foundation
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P2-06-01.
Collapse
Affiliation(s)
- RB Schwab
- University of California, San Diego, La Jolla, CA; Rady Children's Hospital, Division of Genome Information Sciences, University of California, San Diego, La Jolla, CA
| | - L Bao
- University of California, San Diego, La Jolla, CA; Rady Children's Hospital, Division of Genome Information Sciences, University of California, San Diego, La Jolla, CA
| | - M Pu
- University of California, San Diego, La Jolla, CA; Rady Children's Hospital, Division of Genome Information Sciences, University of California, San Diego, La Jolla, CA
| | - B Crain
- University of California, San Diego, La Jolla, CA; Rady Children's Hospital, Division of Genome Information Sciences, University of California, San Diego, La Jolla, CA
| | - Y Dai
- University of California, San Diego, La Jolla, CA; Rady Children's Hospital, Division of Genome Information Sciences, University of California, San Diego, La Jolla, CA
| | - LV Nazareth
- University of California, San Diego, La Jolla, CA; Rady Children's Hospital, Division of Genome Information Sciences, University of California, San Diego, La Jolla, CA
| | - H Matsui
- University of California, San Diego, La Jolla, CA; Rady Children's Hospital, Division of Genome Information Sciences, University of California, San Diego, La Jolla, CA
| | - AM Wallace
- University of California, San Diego, La Jolla, CA; Rady Children's Hospital, Division of Genome Information Sciences, University of California, San Diego, La Jolla, CA
| | - F Hasteh
- University of California, San Diego, La Jolla, CA; Rady Children's Hospital, Division of Genome Information Sciences, University of California, San Diego, La Jolla, CA
| | - O Harismendy
- University of California, San Diego, La Jolla, CA; Rady Children's Hospital, Division of Genome Information Sciences, University of California, San Diego, La Jolla, CA
| | - KA Frazer
- University of California, San Diego, La Jolla, CA; Rady Children's Hospital, Division of Genome Information Sciences, University of California, San Diego, La Jolla, CA
| | - BA Parker
- University of California, San Diego, La Jolla, CA; Rady Children's Hospital, Division of Genome Information Sciences, University of California, San Diego, La Jolla, CA
| | - K Messer
- University of California, San Diego, La Jolla, CA; Rady Children's Hospital, Division of Genome Information Sciences, University of California, San Diego, La Jolla, CA
| |
Collapse
|
15
|
Knox S, Welsh P, Bezlyak V, McConnachie A, Boulton E, Deans KA, Ford I, Batty GD, Burns H, Cavanagh J, Millar K, McInnes IB, McLean J, Velupillai Y, Shiels P, Tannahill C, Packard CJ, Michael Wallace A, Sattar N. 25-Hydroxyvitamin D is lower in deprived groups, but is not associated with carotid intima media thickness or plaques: results from pSoBid. Atherosclerosis 2012; 223:437-41. [PMID: 22632919 DOI: 10.1016/j.atherosclerosis.2012.05.001] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/02/2012] [Revised: 04/25/2012] [Accepted: 05/01/2012] [Indexed: 12/20/2022]
Abstract
OBJECTIVE The association of the circulating serum vitamin D metabolite 25-hydroxyvitamin D (25OHD) with atherosclerotic burden is unclear, with previous studies reporting disparate results. METHOD Psychological, social and biological determinants of ill health (pSoBid) is a study of participants aged 35-64 years from Glasgow who live at extremes of the socioeconomic spectrum. Vitamin D deficiency was defined as 25OHD < 25nmol/L, as per convention. Cross-sectional associations between circulating 25OHD concentrations and a range of socioeconomic, lifestyle, and biochemistry factors, as well as carotid intima media thickness (cIMT) and plaque presence were assessed in 625 participants. RESULTS Geometric mean levels of circulating 25OHD were higher among the least deprived (45.6 nmol/L, 1-SD range 24.4-85.5) versus most deprived (34.2 nmol/L, 1-SD range 16.9-69.2; p < 0.0001). In the least deprived group 15% were "deficient" in circulating 25OHD versus 30.8% in the most deprived (χ(2)p < 0.0001). Log 25OHD was 27% lower among smokers (p < 0.0001), 20% higher among the physically active versus inactive (p = 0.01), 2% lower per 1 kg/m(2) increase in body mass index (BMI) (p < 0.0001), and showed expected seasonal variation (χ(2)p < 0.0001). Log 25OHD was 13% lower in the most versus least deprived independent of the aforementioned lifestyle confounding factors (p = 0.03). One unit increase in log 25OHD was not associated with atherosclerotic burden in univariable models; cIMT (effect estimate 0.000 mm [95% CI -0.011, 0.012]); plaque presence (OR 0.88 [0.75, 1.03]), or in multivariable models. CONCLUSION There is no strong association of 25OHD with cIMT or plaque presence, despite strong evidence 25OHD associates with lifestyle factors and socioeconomic deprivation.
Collapse
Affiliation(s)
- Susan Knox
- Department of Clinical Biochemistry, Glasgow Royal Infirmary, Glasgow G31 2ER, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Husz ZL, Wallace AM, Green PR. Tracking With a Hierarchical Partitioned Particle Filter and Movement Modelling. IEEE Trans Syst Man Cybern B Cybern 2011; 41:1571-84. [PMID: 21724518 DOI: 10.1109/tsmcb.2011.2157680] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
We present an approach to track human subjects using an articulated human framework. First, we describe the articulated hierarchical human model. Second, we develop a stochastic hierarchical, partitioned, particle filter based on the natural structure and limb dependency of the human body. We apply this to track human subjects in video sequences using likelihoods adapted to the hierarchical process. Finally, we evaluate the effectiveness of the described approach using publicly available datasets.
Collapse
|
17
|
Li HWR, Brereton RE, Anderson RA, Wallace AM, Ho CKM. Vitamin D deficiency is common and associated with metabolic risk factors in patients with polycystic ovary syndrome. Metabolism 2011; 60:1475-81. [PMID: 21550088 DOI: 10.1016/j.metabol.2011.03.002] [Citation(s) in RCA: 139] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/30/2010] [Revised: 03/01/2011] [Accepted: 03/02/2011] [Indexed: 10/18/2022]
Abstract
Both vitamin D deficiency and polycystic ovary syndrome (PCOS) are associated with aspects of metabolic syndrome, but it is unclear whether vitamin D deficiency contributes to the metabolic disturbances commonly found in women with PCOS. This study sought to investigate (1) the prevalence of vitamin D deficiency in PCOS women in Scotland and (2) the relationship between vitamin D status and metabolic risk factors. This was an observational study on 52 women (25 in PCOS group and 27 in control group). Serum 25-hydroxyvitamin D concentrations less than 25 nmol/L were classified as severe vitamin D deficiency and were found in 44.0% and 11.2% of subjects in the PCOS and control groups, respectively (P = .047). Among the PCOS subjects, 25-hydroxyvitamin D concentrations were negatively correlated with body mass index (P = .033), C-reactive protein (P = .027), and free androgen index (P = .025) and positively correlated with quantitative insulin sensitivity check index (P = .035), high-density lipoprotein cholesterol (HDL-C) (P = .033), and sex hormone binding globulin (P = .038). Associations of vitamin D deficiency with quantitative insulin sensitivity check index and HDL-C were independent of body mass index and waist-to-hip ratio. Vitamin D deficiency is highly prevalent in PCOS women in Scotland, and a larger proportion of PCOS patients than control women were found to be vitamin D deficient. We also demonstrate correlations of vitamin D status with insulin sensitivity, HDL-C, and C-reactive protein in PCOS patients, which support the increasing evidence that vitamin D deficiency is associated with multiple metabolic risk factors in PCOS women.
Collapse
Affiliation(s)
- Hang Wun Raymond Li
- Division of Reproductive and Developmental Sciences, The University of Edinburgh, Edinburgh, UK
| | | | | | | | | |
Collapse
|
18
|
Perry RJ, Novikova E, Wallace AM, Donaldson MDC. Pitfalls in the diagnosis of 5α-reductase type 2 deficiency during early infancy. Horm Res Paediatr 2011; 75:380-2. [PMID: 21447938 DOI: 10.1159/000324646] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/11/2011] [Accepted: 01/21/2011] [Indexed: 11/19/2022] Open
|
19
|
Zgaga L, Theodoratou E, Farrington SM, Agakov F, Tenesa A, Walker M, Knox S, Wallace AM, Cetnarskyj R, McNeill G, Kyle J, Porteous ME, Dunlop MG, Campbell H. Diet, environmental factors, and lifestyle underlie the high prevalence of vitamin D deficiency in healthy adults in Scotland, and supplementation reduces the proportion that are severely deficient. J Nutr 2011; 141:1535-42. [PMID: 21697298 PMCID: PMC3361015 DOI: 10.3945/jn.111.140012] [Citation(s) in RCA: 65] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Vitamin D deficiency has recently been implicated as a possible risk factor in the etiology of numerous diseases, including nonskeletal conditions. In humans, skin synthesis following exposure to UVB is a potent source of vitamin D, but in regions with low UVB, individuals are at risk of vitamin D deficiency. Our objectives were to describe the prevalence of vitamin D deficiency and to investigate determinants of plasma 25-hydroxyvitamin D (25-OHD) concentrations in a high northern latitude country. Detailed dietary, lifestyle, and demographic data were collected for 2235 healthy adults (21-82 y) from Scotland. Plasma 25-OHD was measured by liquid chromatography-tandem MS. Among study participants, 34.5% were severely deficient (25-OHD <25 nmol/L) and 28.9% were at high risk of deficiency (25-40 nmol/L). Only 36.6% of participants were at low risk of vitamin D deficiency or had adequate levels (>40 nmol/L). Among participants who were taking supplements, 21.3% had a May-standardized 25-OHD concentration >50 nmol/L, 54.2% had 25-50 nmol/L, and 24.5% had <25 nmol/L, whereas this was 15.6, 43.3, and 41%, respectively, among those who did not take supplements (P < 0.0001). The most important sources of vitamin D were supplements and fish consumption. Vitamin D deficiency in Scotland is highly prevalent due to a combination of insufficient exposure to UVB and insufficient dietary intake. Higher dietary vitamin D intake modestly improved the plasma 25-OHD concentration (P = 0.02) and reduced the proportion of severely deficient individuals (P < 0.0001). In regions with low UVB exposure, dietary and supplement intake may be much more important than previously thought and consideration should be given to increasing the current recommended dietary allowance of 0-10 μg/d for adults in Scotland.
Collapse
Affiliation(s)
- Lina Zgaga
- Centre for Population Health Sciences, University of Edinburgh, Edinburgh EH8 9AG, UK.
| | - Evropi Theodoratou
- Centre for Population Health Sciences, University of Edinburgh, Edinburgh EH8 9AG, UK,Colon Cancer Genetics Group and Academic Coloproctology, Institute of Genetics and Molecular Medicine, University of Edinburgh and MRC Human Genetics Unit, Western General Hospital, Edinburgh, EH4 2XU, UK
| | - Susan M. Farrington
- Colon Cancer Genetics Group and Academic Coloproctology, Institute of Genetics and Molecular Medicine, University of Edinburgh and MRC Human Genetics Unit, Western General Hospital, Edinburgh, EH4 2XU, UK
| | - Felix Agakov
- Centre for Population Health Sciences, University of Edinburgh, Edinburgh EH8 9AG, UK
| | - Albert Tenesa
- Colon Cancer Genetics Group and Academic Coloproctology, Institute of Genetics and Molecular Medicine, University of Edinburgh and MRC Human Genetics Unit, Western General Hospital, Edinburgh, EH4 2XU, UK
| | - Marion Walker
- Colon Cancer Genetics Group and Academic Coloproctology, Institute of Genetics and Molecular Medicine, University of Edinburgh and MRC Human Genetics Unit, Western General Hospital, Edinburgh, EH4 2XU, UK
| | - Susan Knox
- Department of Clinical Biochemistry, Royal Infirmary, Glasgow G4 0SF, UK
| | - A. Michael Wallace
- Department of Clinical Biochemistry, Royal Infirmary, Glasgow G4 0SF, UK
| | - Roseanne Cetnarskyj
- School of Nursing, Midwifery and Social Care, Faculty of Health, Life and Social Sciences, Edinburgh Napier University, Edinburgh, UK
| | - Geraldine McNeill
- Public Health Nutrition Research Group, The Rowett Institute of Nutrition and Health, Bucksburn, Aberdeen AB21 9SB, UK
| | - Janet Kyle
- Public Health Nutrition Research Group, The Rowett Institute of Nutrition and Health, Bucksburn, Aberdeen AB21 9SB, UK
| | - Mary E. Porteous
- Southeast of Scotland Clinical Genetic Services, University of Edinburgh, Western General Hospital, Edinburgh, EH4 2XU, UK
| | - Malcolm G. Dunlop
- Colon Cancer Genetics Group and Academic Coloproctology, Institute of Genetics and Molecular Medicine, University of Edinburgh and MRC Human Genetics Unit, Western General Hospital, Edinburgh, EH4 2XU, UK
| | - Harry Campbell
- Centre for Population Health Sciences, University of Edinburgh, Edinburgh EH8 9AG, UK,Colon Cancer Genetics Group and Academic Coloproctology, Institute of Genetics and Molecular Medicine, University of Edinburgh and MRC Human Genetics Unit, Western General Hospital, Edinburgh, EH4 2XU, UK,To whom correspondence should be addressed. E-mail: or
| |
Collapse
|
20
|
Ahmed SF, Franey C, McDevitt H, Somerville L, Butler S, Galloway P, Reynolds L, Shaikh MG, Wallace AM. Recent trends and clinical features of childhood vitamin D deficiency presenting to a children's hospital in Glasgow. Arch Dis Child 2011; 96:694-6. [PMID: 20584848 DOI: 10.1136/adc.2009.173195] [Citation(s) in RCA: 82] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BACKGROUND The incidence of vitamin D deficiency is unclear in the context of continuing demographic changes and the introduction of new public health measures. METHODS All cases in which vitamin D deficiency was suspected as the primary cause of the clinical presentation were studied. RESULTS Between 2002 and 2008, 160 cases of symptomatic vitamin D deficiency were identified with twice as many cases in 2008 (n, 42) as in the previous years. The median age of the cohort was 24 months (range 2 weeks-14 years).Three cases were recorded in children of European background, whereas the rest were in children of South Asian, Middle Eastern or sub-Saharan ethnic background. Presenting features included bowed legs in 64 (40%) and a fit in 19 (12%). In one infant, concerns were raised following a presentation with cardiac failure and hypocalcaemia. SUMMARY Symptomatic vitamin D deficiency remains prevalent in the West of Scotland. There is a need for effective public health education, action and surveillance.
Collapse
Affiliation(s)
- S F Ahmed
- Department of Child Health, Royal Hospital for Sick Children, Yorkhill, Glasgow, UK.
| | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Ahmed SF, Achermann JC, Arlt W, Balen AH, Conway G, Edwards ZL, Elford S, Hughes IA, Izatt L, Krone N, Miles HL, O'Toole S, Perry L, Sanders C, Simmonds M, Wallace AM, Watt A, Willis D. UK guidance on the initial evaluation of an infant or an adolescent with a suspected disorder of sex development. Clin Endocrinol (Oxf) 2011; 75:12-26. [PMID: 21521344 PMCID: PMC3132446 DOI: 10.1111/j.1365-2265.2011.04076.x] [Citation(s) in RCA: 114] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
It is paramount that any child or adolescent with a suspected disorder of sex development (DSD) is assessed by an experienced clinician with adequate knowledge about the range of conditions associated with DSD. If there is any doubt, the case should be discussed with the regional team. In most cases, particularly in the case of the newborn, the paediatric endocrinologist within the regional DSD team acts as the first point of contact. The underlying pathophysiology of DSD and the strengths and weaknesses of the tests that can be performed should be discussed with the parents and affected young person and tests undertaken in a timely fashion. This clinician should be part of a multidisciplinary team experienced in management of DSD and should ensure that the affected person and parents are as fully informed as possible and have access to specialist psychological support. Finally, in the field of rare conditions, it is imperative that the clinician shares the experience with others through national and international clinical and research collaboration.
Collapse
Affiliation(s)
- S Faisal Ahmed
- Royal Hospital for Sick Children, University of Glasgow, GlasgowDevelopmental Endocrinology, UCL Institute of Child Health, University College London, LondonInstitute of Biomedical Research, University of Birmingham, BirminghamLeeds Centre for Reproductive Medicine, Leeds Teaching Hospitals, LeedsDepartment of Endocrinology, University College London Hospitals, LondonAlder Hey Children's NHS Foundation Trust, LiverpoolCLIMB CAH Support GroupDepartment of Paediatrics, University of Cambridge, CambridgeClinical Genetics Dept, Guys Hospital, LondonDept Clinical Biochemistry, Barts and the London NHS Trust, LondonDepartment Paediatric Urology, Alder Hey NHS Foundation Trust, LiverpoolAIS Support GroupDepartment of Biochemistry, Glasgow Royal Infirmary, Glasgow, UKSociety for Endocrinology, Bristol, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Rezai MR, Wallace AM, Sattar N, Finn JD, Wu FCW, Cruickshank JK. Ethnic differences in aortic pulse wave velocity occur in the descending aorta and may be related to vitamin D. Hypertension 2011; 58:247-53. [PMID: 21670413 DOI: 10.1161/hypertensionaha.111.174425] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
We studied aortic pulse wave velocity (aPWV), a predictor of cardiovascular events independent of blood pressure, in a multiethnic sample of British men, to investigate the roles for blood levels of vitamin D and aldosterone in total and regional aortic stiffness. Total aPWV was estimated noninvasively by the Arteriograph device (aPWV(AG)) in 198 men, with its length measure calibrated by magnetic resonance. PWVs over the aortic arch and descending aorta were measured by magnetic resonance in a subsample (n=47). Mean (SE) aPWV(AG) in South Asians (n=68; age 55±10 years), at known higher coronary disease risk than other groups, was 0.5 m/s (0.2 m/s) higher than in African Caribbeans (n=67; 55±10 years), at lowest coronary disease risk here, and Europeans (n=63; 57±8 years), adjusted for age, systolic blood pressure, and diabetes mellitus (P=0.01). By magnetic resonance, PWV over the descending aorta in South Asians was 0.7 m/s (0.3 m/s) and 0.8 m/s (0.3 m/s) higher than in African Caribbeans and Europeans, respectively; PWV over the aortic arch was not different. South Asians and African Caribbeans had 21 nmol/L (3 nmol/L) and 14 nmol/L (3 nmol/L) lower mean (SE) 25(OH)D than Europeans (P<0.001). Unlike aldosterone, 25(OH)D was negatively correlated with aPWV(AG) adjusted for age and systolic blood pressure, as well as weakened or removed ethnic differences in aPWV(AG) in regression models. These data suggest that aortic stiffness as aPWV parallels coronary disease risk in ethnic groups, descending aortic but not arch PWV has this feature, and serum 25(OH)D is an independent negative correlate of aPWV and may partly account for ethnicity-related differences in aPWV and coronary disease risk.
Collapse
Affiliation(s)
- Mohammad-Reza Rezai
- Diabetes, Nutrition & Cardiovascular Medicine Research Group, Franklin-Wilkins Building level 4, King's College University of London & King's Health Partners, 150 Stamford Street, London SE1 9NH, UK
| | | | | | | | | | | |
Collapse
|
23
|
Wallace AM, Faye SA, Fleming R, Nelson SM. A multicentre evaluation of the new Beckman Coulter anti-Müllerian hormone immunoassay (AMH Gen II). Ann Clin Biochem 2011; 48:370-3. [DOI: 10.1258/acb.2011.010172] [Citation(s) in RCA: 92] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Background The measurement of anti-Müllerian hormone (AMH) has been by two commercial enzyme-linked immunosorbent (ELISA) assays: Diagnostics Systems Laboratory (DSL 10-14400) and Immunotech (A11893 IVD EU only). Beckman Coulter has developed a new assay for AMH (AMH Gen II A79765), which uses the DSL antibodies but is standardized to the Immunotech calibration. As a result, comparative data are urgently required between the old DSL assay and its replacement AMH Gen II. Methods An evaluation of the AMH Gen II assay was performed at three sites, each with extensive experience of measuring circulating AMH in the adult female. Results were compared with the original DSL ELISA assay. The analysis was performed on a total of 271 patients' samples, approximately 90 at each site. Results Performance characteristics were evaluated for the AMHGen II assay. Linearity was acceptable with observed values close to the expected (mean recovery 106.3%). The functional sensitivity (20% coefficient of variation), calculated from precision profile data, was 1.5 pmol/L. Within- and between-batch imprecision, assessed over the concentration range of 5–70 pmol/L, were 5.3–11.4% and 3.8–17.3%, respectively. There was good agreement between assays with a Bablok-Passing regression equation AMH Gen II = 1.40 DSL–0.62 pmol/L, r = 0.96, n = 271. Conclusions Our results demonstrate that similar precision and excellent between-assay agreement should be obtained when laboratories change from the DSL to the AMH Gen II ELISA and they should expect an increase in AMH values of approximately 40%.
Collapse
Affiliation(s)
- A M Wallace
- Department Clinical Biochemistry, Glasgow Royal Infirmary, Glasgow, UK
| | - S A Faye
- Beckman Coulter Inc, 22 Rue Juste-Olivier, 1260 Nyon, Switzerland
| | - R Fleming
- Glasgow Centre for Reproductive Medicine
| | - S M Nelson
- Centre for Population and Health Sciences, University of Glasgow, Level 2 McGregor Building, Western Infirmary, Glasgow G12 8QQ, UK
| |
Collapse
|
24
|
Reid D, Toole BJ, Knox S, Talwar D, Harten J, O'Reilly DSJ, Blackwell S, Kinsella J, McMillan DC, Wallace AM. The relation between acute changes in the systemic inflammatory response and plasma 25-hydroxyvitamin D concentrations after elective knee arthroplasty. Am J Clin Nutr 2011; 93:1006-11. [PMID: 21411617 DOI: 10.3945/ajcn.110.008490] [Citation(s) in RCA: 219] [Impact Index Per Article: 16.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Studies indicate that low plasma 25-hydroxyvitamin D [25(OH)D] is associated with a range of disease processes, many of which are inflammatory. However, other lipid-soluble vitamins decrease during the systemic inflammatory response, and this response may confound the interpretation of plasma 25(OH)D. OBJECTIVE The objective was to examine whether plasma 25(OH)D concentrations change during evolution of the systemic inflammatory response. DESIGN Patients (n = 33) who underwent primary knee arthroplasty had venous blood samples collected preoperatively and postoperatively (beginning 6-12 h after surgery and on each morning for 5 d) for the measurement of 25(OH) D, vitamin D-binding protein, parathyroid hormone (PTH), calcium, C-reactive protein, and albumin. A final sample was collected at 3 mo. RESULTS Preoperatively, most patients were 25(OH)D deficient (<50 nmol/L) and had secondary hyperparathyroidism (PTH > 5 pmol/L). Age, sex, body mass index, season, medical history, and medication use were not associated with significant differences in preoperative plasma 25(OH)D concentrations. By day 2 there was a large increase in C-reactive protein concentrations (P < 0.001) and a significant decrease in 25(OH)D of ≈40% (P < 0.001). C-reactive protein, 25(OH)D, and calculated free 25(OH)D had not returned to preoperative concentrations by 5 d postoperatively (all P < 0.001). At 3 mo, 25(OH)D and free 25(OH)D remained significantly lower (20% and 30%, respectively; P < 0.01). CONCLUSION Plasma concentrations of 25(OH)D decrease after an inflammatory insult and therefore are unlikely to be a reliable measure of 25(OH)D status in subjects with evidence of a significant systemic inflammatory response.
Collapse
Affiliation(s)
- David Reid
- Department of Anaesthesia, Faculty of Medicine, University of Glasgow, Royal Infirmary, Glasgow, United Kingdom
| | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Rossi C, Calton L, Brown HA, Gillingwater S, Wallace AM, Petrucci F, Ciavardelli D, Urbani A, Sacchetta P, Morris M. Confirmation of congenital adrenal hyperplasia by adrenal steroid profiling of filter paper dried blood samples using ultra-performance liquid chromatography-tandem mass spectrometry. Clin Chem Lab Med 2011; 49:677-84. [PMID: 21288182 DOI: 10.1515/cclm.2011.109] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND The specificity of screening for congenital adrenal hyperplasia by direct measurement of 17-hydroxyprogesterone in filter paper dried blood spot samples by immunoassay is low and has a high false-positive rate. In order to reduce the false-positive rate of this test, we developed a rapid, robust, specific confirmatory procedure in which cortisol, 4-androstene-3,17-dione and 17-hydroxyprogesterone were measured simultaneously by ultra-performance liquid chromatography-tandem mass spectrometry. METHODS After extraction, samples were analysed by ultra-performance liquid chromatography-tandem mass spectrometry and 17-hydroxyprogesterone was quantified accurately. Other steroids were determined using stable deuterated internal standards. In total, 25 patient blood spot samples and 92 control samples were analysed. RESULTS The assay was linear for 17-hydroxyprogesterone, with a coefficient of determination >0.997 and imprecision ≤ 6.5%. An upper limit of normal for 17-hydroxyprogester-one of 4.45 nmol/L was established by analysing a cohort of samples from unaffected newborns. In addition, a cut-off of 3.5 for the peak areas ratio (17-hydroxyprogesterone+4-androstene-3,17-dione)/cortisol, allows confirmation of the affected steroidogenic enzyme. CONCLUSIONS A high throughput method for the detection of steroids related to congenital adrenal hyperplasia has been developed, allowing the false-positive rate associated with screening for 17-hydroxyprogesterone by immunoassay to be determined.
Collapse
Affiliation(s)
- Claudia Rossi
- Centre of Study on Aging (CeSI), G. d'Annunzio University Foundation, Chieti, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Gaffney D, Howie AF, Bakkush AME, Hoffmann TM, Mason JI, Wallace AM, Donaldson MDC. Functional characterisation of the H365Y mutation of the 21-hydroxylase gene in congenital adrenal hyperplasia. J Steroid Biochem Mol Biol 2011; 123:109-14. [PMID: 21134444 DOI: 10.1016/j.jsbmb.2010.11.013] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/04/2010] [Revised: 11/25/2010] [Accepted: 11/26/2010] [Indexed: 11/15/2022]
Abstract
The study subject was a 13 day-old boy admitted to hospital, with weight loss since birth. He presented with the vomiting and hypotension that are classical features of congenital adrenal hyperplasia (CAH). The most common type of CAH is an autosomal recessive disorder caused by mutations in the 21-hydroxylase (CYP21A2) gene. To examine the CYP21A2 gene, gene-specific PCR was carried out, followed by sequencing. The baby was shown to be a compound heterozygote H365Y/R356W for two CYP21A2 gene mutations each inherited from a different parent. One of the mutations has not previously been functionally characterised. The mutations were reconstructed in an expression plasmid and characterised in vitro after transient transfection into human embryonic kidney (HEK293T) and hepatoblastoma (C3A) cell lines followed by measurement of enzyme activity. The CYP21A2 H365Y mutant exhibited minimal 21-hydroxylase activity to convert 17-hydroxyprogesterone to 11-deoxycortisol or progesterone to 11-deoxycorticosterone. Western immunoblotting indicated that the H365Y enzyme was produced in more variable amounts than wild type; in particular, the H365Y mutant protein may be unstable and/or subject to a more rapid degradation by the human proteosome as well as catalytically inefficient. The double mutant genotype with a severe mutation on each allele is compatible with the clinical presentation.
Collapse
Affiliation(s)
- Dairena Gaffney
- Department of Biochemistry, Glasgow Royal Infirmary, Glasgow G4 0SF, United Kingdom.
| | | | | | | | | | | | | |
Collapse
|
27
|
Hill D, Nibbe A, Lomo L, Royce M, Wallace AM, Bocklage T. Abstract P3-12-06: Biomarkers of Malignant Potential in Breast Tissue in Relation to Short-Term Breast Cancer Risk. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p3-12-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Biomarkers expressed in benign or normal breast tissue may be important indicators of subsequent risk of malignancy, but investigations identifying such have been few. Limited previous evidence suggests that loss of expression of several breast cancer tumor markers in benign tissue, relative to normal tissue, may contribute to malignant progression. We examined expression of markers implicated in tumorigenesis among women who developed breast cancer shortly after benign biopsy. Material and Methods:
We conducted a nested case-control study within a population-based cohort of 15,000 women who received benign breast biopsies between 1996 and 2005 in six New Mexico counties. We identified 95 women who developed breast cancer within 5 years of biopsy, and matched them to 3 similar controls who did not develop cancer. Benign breast as well as adjacent normal tissue was assayed using immunohistochemistry for epithelial and stromal markers plausibly related to risk of cancer development. Logistic regression models were employed to estimate odds ratios and 95% confidence intervals for breast cancer risk after adjustment for age, race/ethnicity, and risk category of benign biopsy. Results:
Women who expressed estrogen receptor alpha in their normal tissue (10% or greater staining) had a 2.9-fold increased breast cancer risk (95% confidence interval (CI) 1.0-8.3). Those who expressed Cytokeratin 5/6 (Odds ratio (OR) 3.3; 95% CI 1.2-8.8) or Her2/neu (30% or greater staining) (OR 8.2; 95% CI 0.9-70.6) in normal tissue also appeared to have an elevated breast cancer risk, relative to those with expression below the threshold. In contrast, the presence of these markers in benign tissue was unrelated to subsequent development of breast cancer. Estrogen receptor staining of 10% or greater in normal tissue, but absence of staining in benign tissue, was not a risk factor for progression to breast malignancy (OR 4.9; 95% CI 0.7-34.8) Discussion:
Our results suggest that biomarker expression in normal breast tissue may be an important component of risk assessment among women whoreceive benign breast biopsies. Findings such as these aim to identify women at highest risk for breast cancer development, allowing for the implementation of more frequent follow-up and new targeted interventions, while classifying most women as at low risk, providing reassurance and reducing the need for chemoprevention.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P3-12-06.
Collapse
Affiliation(s)
- D Hill
- University of New Mexico, Albuquerque
| | - A Nibbe
- University of New Mexico, Albuquerque
| | - L Lomo
- University of New Mexico, Albuquerque
| | - M Royce
- University of New Mexico, Albuquerque
| | | | | |
Collapse
|
28
|
Zhao C, Bolan P, Lakkadi N, Sillerud L, Royce M, Wallace AM, Eberhardt SC, Lee SJ, Lomo L, Posse S. Abstract P2-06-16: Total Choline Measurement in Human Breast Using High-Speed MR Spectroscopic Imaging at 3T. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p2-06-16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
PURPOSE: We developed a novel, quantitative and high-speed MR spectroscopic imaging (MRSI) method to map total Choline (tCho), a sensitive biomarker of breast tumor status, as an adjunct to enhance the limited specificity of routine dynamic-contrast enhanced (DCE) MRI. Quantitative tCho maps measured in 7 minutes were compared with tCho obtained with conventional Single Voxel Spectroscopy (SVS). METHOD AND MATERIALS: Measurements on a total of 18 healthy female subjects (mean age: 25.6±5) were performed using 3T MR scanners (Siemens Trio, Erlangen, Germany) located at the two partner sites equipped with 4-channel breast coil (Siemens, Erlangen, Germany) or 8-channel breast coil (Sentinelle Medical, Toronto, Canada). 2D MRSI data of an entire oblique slice were collected using Proton-Echo-Planar-Spectroscopic-Imaging (PEPSI) [1] with MEGA lipid suppression. Acquisition parameters were: TR/TE=1500ms/125ms, matrix size=32x32, voxel size=2x2x2mm3 (8cc), number of signal averages= 16 with weighted k-space sampling and total acquisition time=7 minutes. PRESS SVS data were acquired with 8 cc voxel size using identical TR/TE and acquisition time. The absolute metabolite concentration was calculated in reference to tissue water (millimoles of tCho per kilogram of solute) using LCModel (s-provencher.com) fitting to estimate the Choline peak baseline and subsequent spectral integration using a Cramer-Rao lower bound threshold of 25%.
RESULTS: tCho was detected in 7 of the 15 subjects (47%) in both SVS and PEPSI data. In the PEPSI data sets, tCho was detected in multiple voxels (Fig. 1). Subjects in which tCho was detected exhibited narrower water line width and smaller lipid content than subjects in which tCho was not detectable (2-tailed t-test, P<0.01). The absolute tCho concentrations corrected for relaxation effects in these 7 subjects using SVS and PEPSI was 0.43±0.34 mmol/kg and 0.51±0.19 mmol/kg, respectively. In comparison with SVS data (21.8±8.6Hz), PEPSI spectra demonstrated larger water line width (33.9±12.6Hz) and displayed greater lipid contamination from adipose tissue areas and larger baseline distortion due to the spatial point spread function.
CONCLUSION: Despite less favorable shimming and lipid suppression conditions compared to SVS, it is feasible to quantitatively map tCho in healthy breast tissue using high-speed MRSI, with concentration values that are consistent with those from SVS. Studies in breast cancer patients are in progress to assess the feasibility of breast cancer diagnosis and treatment monitoring with MRSI. Results will be reported at the Symposium. The long-term goals are to utilize high-speed MRSI as an early predictor of treatment failure in women undergoing systemic therapy (i.e. chemotherapy, endocrine therapy) for breast cancer and to develop an improved screening protocol for high risk patients. Fig. 1: PEPSI slice localization (left) and spectral array (right) with superimposed LCModel fit and integrated tCho peak
Ref: (1) Posse et al. Magn. Reson. Med. 2007;58(2):236-244.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P2-06-16.
Collapse
Affiliation(s)
- C Zhao
- University of New Mexico School of Medicine; CMRR, University of Minnesota
| | - P Bolan
- University of New Mexico School of Medicine; CMRR, University of Minnesota
| | - N Lakkadi
- University of New Mexico School of Medicine; CMRR, University of Minnesota
| | - L Sillerud
- University of New Mexico School of Medicine; CMRR, University of Minnesota
| | - M Royce
- University of New Mexico School of Medicine; CMRR, University of Minnesota
| | - AM Wallace
- University of New Mexico School of Medicine; CMRR, University of Minnesota
| | - SC Eberhardt
- University of New Mexico School of Medicine; CMRR, University of Minnesota
| | - S-J Lee
- University of New Mexico School of Medicine; CMRR, University of Minnesota
| | - L Lomo
- University of New Mexico School of Medicine; CMRR, University of Minnesota
| | - S. Posse
- University of New Mexico School of Medicine; CMRR, University of Minnesota
| |
Collapse
|
29
|
Welsh P, Peters MJL, McInnes IB, Lems WF, Lips PT, McKellar G, Knox S, Michael Wallace A, Dijkmans BAC, Nurmohamed MT, Sattar N. Vitamin D deficiency is common in patients with RA and linked to disease activity, but circulating levels are unaffected by TNFα blockade: results from a prospective cohort study. Ann Rheum Dis 2010; 70:1165-7. [DOI: 10.1136/ard.2010.137265] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
30
|
Connell NA, Paterson WF, Wallace AM, Donaldson MDC. Adrenal function and mortality in children and adolescents with Prader-Willi syndrome attending a single centre from 1991-2009. Clin Endocrinol (Oxf) 2010; 73:686-8. [PMID: 20718763 DOI: 10.1111/j.1365-2265.2010.03853.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
31
|
Roxburgh CSD, Wallace AM, Guthrie GK, Horgan PG, McMillan DC. Comparison of the prognostic value of tumour- and patient-related factors in patients undergoing potentially curative surgery for colon cancer. Colorectal Dis 2010; 12:987-94. [PMID: 19555389 DOI: 10.1111/j.1463-1318.2009.01961.x] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
AIM To comprehensively compare the prognostic value of tumour- and patient-related factors in patients undergoing curative surgery for colon cancer. METHOD From a database of 287 patients who underwent elective resection between 1997 and 2005, tumour factors including stage and host factors including systemic inflammatory response [modified Glasgow Prognostic Score (mGPS)] were identified. RESULTS Median follow-up was 65 months. Over this period, 125 patients died, 80 from cancer. On multivariate analysis of all significant patient and tumour related factors, Dukes stage (P < 0.01), vascular invasion (P < 0.01) and the mGPS (P < 0.01) were independently associated with cancer-survival. Of the patient-related factors, age (P < 0.01), haemoglobin (P < 0.01), white-cell (P < 0.01), neutrophil (P < 0.01) and platelet (P < 0.01) counts, and alkaline phosphatase (P < 0.01) were most significantly associated with the mGPS. CONCLUSION In addition to tumour-related factors such as Dukes stage and vascular invasion, the preoperative mGPS should be included to guide prognosis in patients undergoing curative resection for colon cancer.
Collapse
Affiliation(s)
- C S D Roxburgh
- University Department of Surgery, Faculty of Medicine - University of Glasgow, Royal Infirmary, Glasgow, UK.
| | | | | | | | | |
Collapse
|
32
|
Nelson SM, Messow MC, Wallace AM, Fleming R, McConnachie A. Nomogram for the decline in serum antimüllerian hormone: a population study of 9,601 infertility patients. Fertil Steril 2010; 95:736-41.e1-3. [PMID: 20869051 DOI: 10.1016/j.fertnstert.2010.08.022] [Citation(s) in RCA: 114] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2010] [Revised: 07/23/2010] [Accepted: 08/10/2010] [Indexed: 11/17/2022]
Abstract
OBJECTIVE To define an optimal model for the decline in circulating antimüllerian hormone (AMH) with age and develop a validated age-related nomogram. DESIGN Cohort study with validation of linear, biphasic linear, differential, power, and quadratic equations undertaken in two additional cohorts. SETTING United Kingdom infertility clinics. PATIENT(S) Training cohort of 4,590 infertile women. Two separate validation cohorts; 4,588 infertile women, and 423 women with confirmed ovulation and normal pelvic ultrasound who have a male partner with severe oligospermia. INTERVENTION(S) Serum AMH measurement. MAIN OUTCOME MEASURE(S) Optimal fit and age-related AMH nomogram. RESULT(S) The linear model had the largest sum of absolute and squared residuals and provided a less adequate fit than the four nonlinear models. Of these, the R(2) ranged from 19.45% to 19.48% in the training dataset, from 21.30% to 21.36% in the validation dataset, and from 13.29% to 13.75% in the partners of oligospermic males. The parameters of the differential model were difficult to estimate, and the goodness-of-fit of the power model was slightly inferior to the quadratic model. CONCLUSION(S) Circulating AMH concentrations decline with increasing reproductive age in a manner optimally described by a quadratic equation. This validated age-related AMH nomogram will enable counseling of infertility patients regarding reproductive performance.
Collapse
Affiliation(s)
- Scott M Nelson
- Reproductive and Maternal Medicine, Faculty of Medicine, University of Glasgow, Glasgow, Scotland.
| | | | | | | | | |
Collapse
|
33
|
Wallace AM, Gibson S, de la Hunty A, Lamberg-Allardt C, Ashwell M. Measurement of 25-hydroxyvitamin D in the clinical laboratory: current procedures, performance characteristics and limitations. Steroids 2010; 75:477-88. [PMID: 20188118 DOI: 10.1016/j.steroids.2010.02.012] [Citation(s) in RCA: 201] [Impact Index Per Article: 14.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/22/2009] [Revised: 02/15/2010] [Accepted: 02/16/2010] [Indexed: 12/19/2022]
Abstract
In this review we describe procedures, performance characteristics and limitations of methods available for the measurement of 25-hydroxyvitamin (25OHD) since the year 2000. The two main types of methods are competitive immunoassay and those based on chromatographic separation followed by non-immunological direct detection (HPLC, LC-MS/MS). Lack of a reference standard for 25OHD has, until recently, been a major issue resulting in poor between-method comparability. Fortunately this should soon improve due to the recent introduction of a standard reference material in human serum (SRM 972) from the National Institute of Standards and Technology (NIST). For immunoassay, specificity can be an issue especially in relation to the proportion of 25OHD2 that is quantified whereas HPLC and LC-MS/MS methods are able to measure the two major vitamin D metabolites 25OHD2 and 25OHD3 independently. HPLC and LC-MS/MS require more expensive equipment and expert staff but this can be offset against lower reagent costs. Increasingly procedures are being developed to semi-automate or automate HPLC and LC-MS/MS but run times remain considerably longer than for immunoassays especially if performed on automated platforms. For most HPLC and LC-MS/MS methods extraction and procedural losses are corrected for by the inclusion of an internal standard which, in part, may account for higher results compared to immunoassay. In general precision of immunoassay, HPLC and LC-MS/MS are comparable and all have the required sensitivity to identify severe vitamin D deficiency. Looking to the future it is hoped that the imminent introduction of a standard reference method (or methods) for 25OHD will further accelerate improvements in between method comparability.
Collapse
Affiliation(s)
- A M Wallace
- Department of Clinical Biochemistry, Macewen Building, Royal Infirmary, Glasgow G4 0SF, UK.
| | | | | | | | | |
Collapse
|
34
|
Ahmed SF, Keir L, McNeilly J, Galloway P, O'Toole S, Wallace AM. The concordance between serum anti-Mullerian hormone and testosterone concentrations depends on duration of hCG stimulation in boys undergoing investigation of gonadal function. Clin Endocrinol (Oxf) 2010; 72:814-9. [PMID: 19811508 DOI: 10.1111/j.1365-2265.2009.03724.x] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND In boys undergoing investigation of gonadal function, the relationship between a single measurement of serum anti-Mullerian hormone (AMH) and hCG stimulated serum testosterone is unclear. AIM The aim of the study was to assess concordance between serum AMH and testosterone concentrations following hCG stimulation of two different durations. METHODS Samples from 284 children (M : F, 154 : 130) with a median age of 8 years (10th, 90th centiles, 0.25, 14) were used to establish an AMH reference range. Clinical data were reviewed in boys undergoing investigation of gonadal function and who had an AMH measurement and a hCG stimulated (3-day or 3-week) (n = 26) testosterone. Of these 26 boys, 11 had combined genital anomalies, whereas the rest had conditions such as isolated hypospadias, undescended testes or microphallus. Normal testosterone response to hCG stimulation was defined as a level greater than 3.5 nmol at day 4 and 9.5 nmol/l at day 22. RESULTS In the reference group, the 5th centile AMH for boys below 1 year was 215 pmol/l and between 1 and 8 years 180 pmol/l. The 95th centile for girls for these respective age groups was 30 pmol/l and 25 pmol/l. In those cases where serum testosterone concentrations were available at day 1, day 4 and day 22 of the 3 week-hCG test, five cases had a normal serum testosterone at day 4 and three cases only showed such a response by day 22. In those where serum AMH was less than 180 pmol/l, a poor testosterone response of less than 3.5 nmol was observed in approximately seven of eight (88%) cases with a 3-day hCG stimulation test or the 3-week test. An AMH of greater than 180 pmol/l was associated with a normal testosterone response at day 4 in 10 out of 15 (67%) cases and at day 22 in eight of 11 (73%) cases. However, a low serum testosterone concentration of less than 3.5 nmol after the 3-day hCG test was only associated with a likelihood of a low AMH in three of eight (37%) cases. With the 3-week hCG test, a low day 22 testosterone of 9.5 mmol/l or less was associated with a low AMH of 180 pmol/l or less in four of seven (57%) cases. CONCLUSION In boys undergoing investigation of gonadal function, the concordance between AMH and testosterone is better at day 22 than day 4. A normal AMH may provide useful information on overall testicular function but does not exclude the need for an hCG stimulation test.
Collapse
Affiliation(s)
- S F Ahmed
- Department of Child Health, Royal Hospital for Sick Children, Glasgow, UK.
| | | | | | | | | | | |
Collapse
|
35
|
Affiliation(s)
- A Mason
- Royal Hospital for Sick Children, Glasgow G3 8SJ
| | | | | | | | | |
Collapse
|
36
|
Dorrian CA, Toole BJ, Alvarez-Madrazo S, Kelly A, Connell JMC, Wallace AM. A screening procedure for primary aldosteronism based on the Diasorin Liaison® automated chemiluminescent immunoassay for direct renin. Ann Clin Biochem 2010; 47:195-9. [DOI: 10.1258/acb.2010.009230] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Background Primary aldosteronism (PA), the most common secondary cause of hypertension, can be screened for using the aldosterone/renin ratio. This ratio is raised in PA and its accuracy depends on the ability to measure plasma renin at extremely low concentrations. Methods We compared two different procedures for assessing plasma renin. The conventional method, which measures plasma renin activity (PRA), is technically demanding and laborious, and the Diasorin Liaison® method, which measures plasma renin concentration (PRC), is an automated immunoassay. Results from each method were used to calculate the aldosterone/renin ratio (ARR) and the performance of the Diasorin Liaison® method compared with that of the conventional assay using receiver operator characteristic curves. Results The analytical and functional sensitivity of the PRC method were 2.1 and 5 μIU/mL, respectively. Intra- and inter-assay precision were <7.2% and 10.4%, respectively. There was significant (9%) prorenin interference. Samples with PRA > 1.0 ng/mL/h showed significant correlation with PRC ( r = 0.93; P < 0.05; n = 146); however, with PRA < 1.0 ng/mL/h, no significant correlation occurred ( r = 0.14; P < 0.05; n = 79). An aldosterone (pmol/L)/PRC(μIU/mL) ratio of >35, in patients with aldosterone >300 pmol/L, resulted in 100% sensitivity and 93% specificity, when compared with the commonly accepted aldosterone (pmol/L)/PRA (ng/mL/h) ratio of >750, in identifying patients who may suffer from PA. Conclusion This study indicates the feasibility of using the automated PRC assay as a replacement for the conventional manual PRA assay in calculating the ARR as a first-line screen for PA.
Collapse
Affiliation(s)
- C A Dorrian
- Department of Clinical Biochemistry, Macewen Building, Royal Infirmary, Glasgow G4 0SF
| | - B J Toole
- Department of Clinical Biochemistry, Macewen Building, Royal Infirmary, Glasgow G4 0SF
| | - S Alvarez-Madrazo
- BHF Glasgow Cardiovascular Research Centre, Faculty of Medicine, University of Glasgow, Glasgow G12 8TA, Scotland
| | - A Kelly
- Department of Clinical Biochemistry, Macewen Building, Royal Infirmary, Glasgow G4 0SF
| | - J M C Connell
- BHF Glasgow Cardiovascular Research Centre, Faculty of Medicine, University of Glasgow, Glasgow G12 8TA, Scotland
| | - A M Wallace
- Department of Clinical Biochemistry, Macewen Building, Royal Infirmary, Glasgow G4 0SF
| |
Collapse
|
37
|
Paterson WF, Ahmed SF, Bath L, Donaldson MDC, Fleming R, Greene SA, Hunter I, Kelnar CJH, Mayo A, Schulga JS, Shapiro D, Smail PJ, Wallace AM. Exaggerated adrenarche in a cohort of Scottish children: clinical features and biochemistry. Clin Endocrinol (Oxf) 2010; 72:496-501. [PMID: 19863577 DOI: 10.1111/j.1365-2265.2009.03739.x] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
OBJECTIVE To investigate the reported association between exaggerated adrenarche (EA) and reduced foetal growth and to identify possible risk factors for future morbidity in Scottish children with clinical features of EA. DESIGN Three-year prospective study. MEASUREMENTS Auxology, blood pressure (BP), biochemical analysis of blood and urine, pelvic ultrasound in girls. RESULTS Fifty-two patients were recruited of whom one girl had nonclassical congenital adrenal hyperplasia (17-OHP 17 nmol/l) and one had insufficient blood for analysis. The final cohort comprised 42 girls of mean (SD) age 7.7 (0.99) and eight boys of 8.8 (0.67) years. Mean (SD) birth weight was 3.27 (0.49) and 3.10 (0.76) kg in girls and boys respectively. Height/weight SDS were 1.13/1.69 in girls and 1.69/1.88 in boys. Mean systolic/diastolic BP was 107.8/60.4 (50th-75th centile) in girls and 115.5/63.9 (75th-91st centile) in boys. Uterine and ovarian development was prepubertal. Median serum dehydroepiandrosterone sulphate (DHEAS) was 2.1 and 4.1 mumol/l, androstenedione 3.1 and 3.8 nmol/l in girls and boys respectively, with DHEAS within the reference range/undetectable in 18/2 and androstenedione in 12/6 patients. Fasting insulin was 9.0 and 15.0 mU/l in girls and boys respectively, with concomitant low normal SHBG. Anti-Mullerian hormone (AMH) was 15.7 pmol/l in 27 girls, compared with 5.0 pmol/l in normal girls aged 5-8 years. CONCLUSIONS Our Scottish EA cohort showed female predominance, no evidence of reduced foetal growth, a tendency to overweight with commensurate mild hyperinsulinaemia and modest elevation of serum androgens in some patients. We have found raised AMH levels in the girls, indicating advanced ovarian follicular development.
Collapse
|
38
|
Meek CL, Wallace AM, Forrest LM, McMillan DC. The relationship between the insulin-like growth factor-1 axis, weight loss, an inflammation-based score and survival in patients with inoperable non-small cell lung cancer. Clin Nutr 2010; 29:206-9. [DOI: 10.1016/j.clnu.2009.08.013] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2008] [Revised: 06/24/2009] [Accepted: 08/25/2009] [Indexed: 10/20/2022]
|
39
|
Rossi C, Calton L, Hammond G, Brown HA, Wallace AM, Sacchetta P, Morris M. Serum steroid profiling for Congenital Adrenal Hyperplasia using liquid chromatography–tandem mass spectrometry. Clin Chim Acta 2010; 411:222-8. [DOI: 10.1016/j.cca.2009.11.007] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2009] [Revised: 08/24/2009] [Accepted: 11/06/2009] [Indexed: 11/24/2022]
|
40
|
Alvarez-Madrazo S, Padmanabhan S, Mayosi BM, Watkins H, Avery P, Wallace AM, Fraser R, Davies E, Keavney B, Connell JM. Familial and phenotypic associations of the aldosterone Renin ratio. J Clin Endocrinol Metab 2009; 94:4324-33. [PMID: 19820005 DOI: 10.1210/jc.2009-1406] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
CONTEXT The aldosterone to renin ratio (ARR) is a marker of aldosterone excess, widely used to screen for primary aldosteronism (PA). The significance of a raised ARR in normotensive and hypertensive subjects and the phenotypic and familial factors affecting it are unclear. OBJECTIVE We estimated the distribution and heritability of the ARR and tested for associations between ARR and blood pressure (BP) with 11 polymorphisms at the CYP11B1/CYP11B2 locus. DESIGN AND SETTING A total of 1172 individuals from 248 Caucasian families ascertained via a hypertensive proband were evaluated. MAIN OUTCOME MEASURE Plasma aldosterone was measured by RIA, and plasma renin concentration was measured by the LIAISON Direct Renin chemiluminescent immunoassay. RESULTS Unadjusted and adjusted ARR were continuously distributed in normotensives and hypertensives, with no evidence of a cutoff that would identify a separate population with PA. Median ARR was 4.19 ng/liter per mIU/liter (range, 0.04-253.16). ARR levels were higher in females and associated with age, body mass index, and potassium. Antihypertensive agents had significant predictable effects on the ARR. Renin was negatively associated, and ARR was positively associated with ambulatory BP readings (P < 0.001) in subjects not taking antihypertensives. The heritability of the ARR was 38.1% (P < 10(-8)). Plasma aldosterone, but not ARR, was influenced by the intron 2 conversion variation in the CYP11B2 gene (beta = -0.07; P = 0.04). CONCLUSIONS The ARR is continuously distributed, is influenced by genetic and environmental factors, and is not a marker of a distinct pathological abnormality but possibly reflects the long-term influence of aldosterone on cardiovascular homeostasis.
Collapse
Affiliation(s)
- Samantha Alvarez-Madrazo
- Faculty of Medicine, University of Glasgow, British Heart Foundation Glasgow Cardiovascular Research Centre, Glasgow G12 8TA, United Kingdom
| | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Kidd S, Midgley P, Lone N, Wallace AM, Nicol M, Smith J, McIntosh N. A re-investigation of saliva collection procedures that highlights the risk of potential positive interference in cortisol immunoassay. Steroids 2009; 74:666-8. [PMID: 19463688 DOI: 10.1016/j.steroids.2009.02.009] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/18/2008] [Revised: 01/22/2009] [Accepted: 02/21/2009] [Indexed: 11/18/2022]
Abstract
BACKGROUND The use of saliva for measurement of cortisol permits non-invasive study of adrenal function, but collection can be technically difficult, particularly in small infants. Saliva collection can be assisted by citric acid to increase saliva flow, or by the use of cotton or polyester swabs in the mouth. AIM To determine whether different methods of saliva collection affect cortisol radioimmunoassay (RIA) performance. EXPERIMENTAL Cortisol was measured in saliva collected from 16 adults using intra-oral cotton swabs or polyester swabs, compared with saliva dribbled directly into a pot either alone (plain saliva) or after citric acid had been placed on the tongue. An in-house RIA, without prior extraction, was used to measure cortisol with an encapsulated sheep antibody. RESULTS Mean (median) salivary cortisol was 10.9 (10.5) nmol L(-1) in plain saliva, 10.4 (8.4) nmol L(-1) in citric acid stimulated saliva; 25.3 (25.1) nmol L(-1) in saliva collected on cotton swabs, and 27.9 (27.3) nmol L(-1) collected on polyester swabs. Cortisol in saliva collected using citric acid was not significantly different from plain saliva (p=0.997), but cortisol in saliva collected using cotton and polyester swabs was significantly higher than that of plain saliva (p<0.01). CONCLUSION The use of cotton or polyester swabs for collection of saliva can result in spuriously high levels of cortisol when measured by RIA.
Collapse
Affiliation(s)
- Susan Kidd
- Department of Child Life and Health, University of Edinburgh, 20 Sylvan Place, Edinburgh EH9, UK
| | | | | | | | | | | | | |
Collapse
|
42
|
McGowan R, Tucker P, Joseph D, Wallace AM, Hughes I, Burrows NP, Ahmed SF. Short‐term growth and bone turnover in children undergoing occlusive steroid (‘Wet‐Wrap’) dressings for treatment of atopic eczema. J DERMATOL TREAT 2009; 14:149-52. [PMID: 14522624 DOI: 10.1080/09546630310004207] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
To assess the effects of steroid wet-wrap therapy on short-term growth and bone turnover, eight prepubertal (M:F,5:3) children with a median age of 5.1years (range 3.3-8.8) were studied over a 2-week period prior to therapy and at 2-week intervals during therapy. Short-term growth was assessed by measuring lower leg length velocity (LLLV) by knemometry and bone and collagen turnover was assessed by urinary deoxypyridinoline crosslink excretion corrected for creatinine excretion (DPD). Median duration of study during occlusive dressings was 12 weeks (range 2-18). Topical beclomethasone dipropionate diluted 1:10 or 1:4 in white soft paraffin was applied under tubular (Tubifast) bandages in 7/8 children. Median LLLV before and during therapy were 0.43 mm/week (10(th),90(th) centile; 0.0,0.7) and 0.42 mm/week (10(th),90(th) centile; -0.35,1.01), respectively (not significant). Median DPD before and during therapy were 25.9 nmol/l/creatinine (10(th),90(th) centile; 20.8, 33.0) and 26.3 nmol/l/creatinine (10(th),90(th) centile; 21.7, 34.1) respectively (not significant). Non-invasive assessment of the effects of steroid wet-wrap therapy can be performed in children with eczema. These preliminary results show no substantial growth promoting or adverse effects of therapy.
Collapse
Affiliation(s)
- R McGowan
- Department of Child Health, Royal Hospital For Sick Children, Yorkhill, Glasgow, UK
| | | | | | | | | | | | | |
Collapse
|
43
|
Knox S, Harris J, Calton L, Wallace AM. A simple automated solid-phase extraction procedure for measurement of 25-hydroxyvitamin D3 and D2 by liquid chromatography-tandem mass spectrometry. Ann Clin Biochem 2009; 46:226-30. [DOI: 10.1258/acb.2009.008206] [Citation(s) in RCA: 72] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Background Measurement of 25-hydroxyvitamin D3 (25OHD3) and D2 (25OHD2) is challenging. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods have been described but they are often complex and difficult to automate. We have developed a simplified procedure involving an automated solid-phase extraction (SPE). Methods Internal standard (hexadeuterated 25-hydroxyvitamin D3) was added to serum or plasma followed by protein precipitation with methanol. Following centrifugation, a robotic instrument (CTC PAL [Presearch] for ITSP™ SPE [MicroLiter Analytical Supplies, Inc]) performed a six-step SPE procedure and the purified samples were injected into the LC-MS/MS. Quantification of 25OHD3 and 25OHD2 was by electrospray ionization MS/MS in the multiple-reaction monitoring mode. Results The lower limit of quantitation was 4.0 nmol/L for 25OHD3 and 7.5 nmol/L for 25OHD2. Within- and between-assay precision was below 10% over the concentration range of 22.5–120 nmol/L for D3 and 17.5–70 nmol/L for D2 ( n = 10). The calibration was linear up to 2500 nmol/L ( r = 0.99). Recoveries ranged between 89% and 104% for both metabolites and no ion suppression was observed. The results obtained compared well ( r = 0.96) with the IDS-OCTEIA 25-hydroxyvitamin D enzyme immunoassay for samples containing less than 125 nmol/L, at higher concentrations the immunodiagnostic system (IDS) method showed positive bias. Conclusions Our simplified sample preparation and automated SPE method is suitable for the measurement of 25OHD3 and D2 in a routine laboratory environment. The system can process up to 300 samples per day with no cumbersome solvent evaporation step and minimal operator intervention.
Collapse
Affiliation(s)
- Susan Knox
- Department of Clinical Biochemistry, Macewen Building, Glasgow Royal Infirmary, Glasgow G4 0SF
| | - John Harris
- Presearch, Kingsland Business Park, Basingstoke, Hampshire RG24 8PZ
| | | | - A Michael Wallace
- Department of Clinical Biochemistry, Macewen Building, Glasgow Royal Infirmary, Glasgow G4 0SF
| |
Collapse
|
44
|
Løvås K, McFarlane I, Nguyen HH, Curran S, Schwabe J, Halsall D, Bernhardt R, Wallace AM, Chatterjee VKK. A novel CYP11B2 gene mutation in an Asian family with aldosterone synthase deficiency. J Clin Endocrinol Metab 2009; 94:914-9. [PMID: 19116236 DOI: 10.1210/jc.2008-1524] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Abstract
CONTEXT Three siblings of Pakistani origin presented neonatally with isolated hyperreninemic hypoaldosteronism and were well controlled on fludrocortisone therapy during childhood and adolescence. OBJECTIVE/DESIGN These individuals were reevaluated as adults after fludrocortisone withdrawal to investigate the biochemical and molecular basis of their disorder. RESULTS When reassessed off fludrocortisone treatment, hyperreninemic hypoaldosteronism was confirmed in all subjects but with significant hyperkalemia in only one case. Profiling of urinary steroid metabolites showed a biochemical pattern (elevated tetrahydrocorticosterone to 18-hydroxytetrahydro-11-dehydrocorticosterone ratio but normal 18-hydroxytetrahydro-11-dehydrocorticosterone to tetrahydroaldosterone ratio) consistent with partial type 1 aldosterone synthase deficiency. Sequencing of the CYP11B2 gene showed that affected subjects were homozygous for a single nucleotide substitution (T925C) in exon 5, corresponding to a serine to proline mutation (S308P) in the predicted protein, with unaffected family members being heterozygous. Consistent with structural modeling showing that the mutated residue is located within the alpha-helix I, close to the hemebinding, active site of the enzyme, functional characterization of the S308P mutant protein in vitro showed complete loss of enzyme activity. However, administration of dexamethasone further reduced levels of circulating aldosterone and its urinary metabolites in affected subjects, suggesting that some mineralocorticoid biosynthesis occurs in vivo. CONCLUSION We have identified the first CYP11B2 gene defect in a family of Asian origin, associated with a type 1 aldosterone synthase deficiency phenotype. Preservation of some aldosterone production suggests either residual mutant CYP11B2 enzyme activity in vivo or mineralocorticoid biosynthesis via an alternative pathway.
Collapse
Affiliation(s)
- Kristian Løvås
- Department of Medicine, University of Cambridge, Cambridge CB2 1TN, United Kingdom
| | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Sattar N, Wannamethee G, Sarwar N, Chernova J, Lawlor DA, Kelly A, Wallace AM, Danesh J, Whincup PH. Leptin and coronary heart disease: prospective study and systematic review. J Am Coll Cardiol 2009; 53:167-75. [PMID: 19130985 DOI: 10.1016/j.jacc.2008.09.035] [Citation(s) in RCA: 121] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/20/2008] [Revised: 09/16/2008] [Accepted: 09/23/2008] [Indexed: 12/16/2022]
Abstract
OBJECTIVES This study sought to better determine the link between leptin and coronary heart disease (CHD). BACKGROUND Circulating leptin is considered a risk factor for CHD but larger studies are needed. METHODS Leptin levels were measured in 550 men with fatal CHD or nonfatal myocardial infarction and in 1,184 controls nested within a prospective study of 5,661 British men and set in context with a meta-analysis. RESULTS Baseline leptin correlated with body mass index (BMI), blood pressure, total cholesterol, triglyceride, and inflammatory markers; correlations persisted after BMI adjustment. The within-person consistency of leptin values over 4 years (correlation coefficient: 0.79; 95% confidence interval [CI]: 0.73 to 0.83) was higher than those of some established cardiovascular risk factors. In a comparison of individuals in the top third with those in the bottom third of baseline leptin, the age- and town-adjusted odds ratio for CHD was 1.25 (95% CI: 0.96 to 1.62), decreasing to 0.98 (95% CI: 0.72 to 1.34) after adjustment for BMI. A systematic review identified 7 prospective reports with heterogeneous findings (I(2) = 60%, 13% to 82%). The combined adjusted risk ratio across all studies was 1.44 (95% CI: 0.95 to 2.16) in a comparison of extreme thirds of leptin levels. The inconsistency between studies was partially explained by sample size, with combined estimates from studies involving >100 CHD cases (1.28, 95% CI: 0.80 to 2.04) being somewhat weaker than those from smaller studies (1.81, 95% CI: 0.76 to 4.31). CONCLUSIONS Previous studies appear to have overestimated associations of leptin and CHD risk. Our results suggest a moderate association that is largely dependent on BMI.
Collapse
Affiliation(s)
- Naveed Sattar
- BHF Glasgow Cardiovascular Research Centre, Faculty of Medicine, University of Glasgow, Glasgow, Scotland, UK.
| | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Keir LS, O'Toole S, Robertson AL, Wallace AM, Ahmed SF. A 5-year-old boy with cryptorchidism and pubic hair: investigation and management of apparent male disorders of sex development in mid-childhood. Horm Res Paediatr 2009; 71 Suppl 1:87-92. [PMID: 19153514 DOI: 10.1159/000178046] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Late presentation of congenital adrenal hyperplasia as a 46,XX disorder of sex development due to 11-beta hydroxylase deficiency is uncommon. Such a case raises issues regarding appropriate investigation and management. CASE HISTORY A 5-year-old boy who had recently moved to the United Kingdom presented at the endocrinology clinic with recurrent abdominal pain. He was normotensive and had a history of ambiguous genitalia since birth, a relatively small penis, bilateral cryptorchidism and pubic hair. A systematic workup revealed low anti-Mullerian hormone levels for age and sex and elevated serum testosterone, androstenedione and deoxycortisol levels. A urinary steroid profile confirmed a diagnosis of 11-beta hydroxylase deficiency. The child's karyotype was 46,XX. Further genetic analysis revealed a compound heterozygote mutation in the CYP11B1 gene. Ultrasound scan showed evidence of Mullerian structures and accumulation of menstrual blood in the vagina (haematocolpos). Following discussion at a multidisciplinary clinic, the patient did not undergo sex reassignment and subsequently proceeded to surgery for removal of the Mullerian structures. CONCLUSIONS This case emphasizes the importance of a systematic approach to investigation of older children presenting with apparent male undermasculinisation. It also raises important issues about gender reassignment in mid-childhood and the indications for removal of Mullerian organs in a 46,XX boy.
Collapse
Affiliation(s)
- L S Keir
- Scottish Genital Anomaly Network, Yorkhill, Glasgow, UK.
| | | | | | | | | |
Collapse
|
47
|
Wallace AM, De La Puerta B, Trayhorn D, Moores AP, Langley-Hobbs SJ. Feline combined diaphyseal radial and ulnar fractures. A retrospective study of 28 cases. Vet Comp Orthop Traumatol 2009; 22:38-46. [PMID: 19151869] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
Feline combined diaphyseal radial and ulnar fractures were reviewed in a retrospective study of cases that were admitted to two university teaching hospitals. A high incidence of complications was noted, with 6/26 (23.1%) of cases requiring revision surgery. Open fractures were significantly more likely to require revision surgery. The two main repair methods were external skeletal fixation (ESF) or radial plating. The success rate was greater for radial plating, with only 1/10 (10%) cases requiring revision versus 4/14 (28.6%) for ESF. However, ESF tended to be applied to the more complicated fractures. Stabilisation of both bones proved to be an effective repair strategy with only 1/8 cases (12.5%) requiring revision versus 5/18 cases (27.8%) where only one bone was stabilised. Synostoses and radiohumeral luxation were noted as complications associated with the fractures stabilised by ESF. Final limb function following recovery was assessed as 'good' or 'excellent' in 93.3% of cases.
Collapse
Affiliation(s)
- A M Wallace
- Queens Veterinary School Hospital, Department of Veterinary Medicine, University of Cambridge, Madingley Road, Cambridge, CB3 0ES, UK.
| | | | | | | | | |
Collapse
|
48
|
Malkova D, McLaughlin R, Manthou E, Wallace AM, Nimmo MA. Effect of moderate-intensity exercise session on preprandial and postprandial responses of circulating ghrelin and appetite. Horm Metab Res 2008; 40:410-5. [PMID: 18401836 DOI: 10.1055/s-2008-1058100] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
Responses of plasma total ghrelin and appetite were investigated during preprandial and postprandial stages of recovery from a moderate-intensity cycling session. Healthy recreationally active men underwent one exercise and one control trial. In the exercise trial, subjects exercised for approximately 60 minutes, while in the control trial they rested quietly for the same duration. After the intervention, subjects rested for 120 minutes and then consumed a test meal. Measurements were obtained immediately and 120 minutes after the intervention and then during 180 minutes of the postprandial period. The post-intervention concentration of total ghrelin was lower (p<0.05) in the exercise than in the control trial. The modulating effect of exercise was related to the reduction in the postprandial rather than preprandial concentration. Post-intervention scores of appetite were not different between the two trials, but when preprandial and postprandial responses were considered separately, postprandial hunger and desire to eat was higher (p<0.05) in the exercise trial. In summary, during recovery from moderate-intensity exercise, total ghrelin does not respond in a compensatory manner to disturbances in energy balance. Thus, an exercise-induced increase in appetite during the later stages of recovery coinciding with the postprandial state cannot be explained by changes in the plasma concentration of total ghrelin.
Collapse
Affiliation(s)
- D Malkova
- Human Nutrition Section, Division of Developmental Medicine, Medical School, University of Glasgow, United Kingdom
| | | | | | | | | |
Collapse
|
49
|
Freel EM, Ingram M, Wallace AM, White A, Fraser R, Davies E, Connell JMC. Effect of variation in CYP11B1 and CYP11B2 on corticosteroid phenotype and hypothalamic-pituitary-adrenal axis activity in hypertensive and normotensive subjects. Clin Endocrinol (Oxf) 2008; 68:700-6. [PMID: 17980006 DOI: 10.1111/j.1365-2265.2007.03116.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
BACKGROUND Aldosterone is important in the development of hypertension. We have shown that a single nucleotide polymorphism (SNP) (-344T) in the 5' regulatory region (UTR) of the gene encoding aldosterone synthase (CYP11B2) associates with aldosterone excess and hypertension as well as altered adrenal 11-hydroxylation efficiency (deoxycortisol to cortisol). This conversion is carried out by the enzyme 11beta-hydroxylase, encoded by the adjacent gene, CYP11B1. We proposed that the effects of CYP11B2 are explained by linkage disequilibrium (LD) across the CYP11B locus. We have demonstrated high LD across this locus and identified two SNPs in the 5' UTR of CYP11B1 (-1859 G/T, -1889 A/G) that associate with reduced transcription in vitro and altered 11-hydroxylation efficiency in vivo. Accordingly, we hypothesized that the reduced adrenal 11-hydroxylation may lead to chronic resetting of the pituitary-adrenal axis, with chronically increased ACTH drive resulting in aldosterone excess. METHODS To test this, we examined hypothalamic-pituitary-adrenal (HPA) axis activity in hypertensive and normotensive individuals stratified according to genotype at CYP11B2 (-344T/C) and CYP11B1 (-1859 G/T, -1889 A/G). Fifty-six subjects homozygous for CYP11B2 SNP (27 TT, 12 CC), and 38 homozygous for CYP11B1 SNPs (18 TTGG, 20 GGAA) were recruited. Diurnal variation and the effects of dexamethasone suppression and ACTH stimulation on plasma aldosterone, cortisol and ACTH under controlled conditions were studied. RESULTS Subjects with SNPs associated with reduced 11-hydroxylation efficiency (-344T CYP11B2; TTGG CYP11B1) showed reduced inhibition of ACTH after dexamethasone (P = 0.05) and an altered cortisol-ACTH relationship (decreased cortisol-ACTH ratio, P < 0.02). The same individuals also demonstrated close correlations between plasma cortisol and aldosterone (-344T CYP11B2 r = 0.508, P < 0.004; TTGG CYP11B1 r = 0.563, P < 0.003) suggesting that there was common regulation (possibly ACTH) of these hormones in genetically susceptible subjects. CONCLUSIONS Variation in CYP11B2 and CYP11B1 associates with chronic up-regulation of the HPA axis. These novel data support the suggestion that chronic aldosterone excess, in genetically susceptible individuals, may be a consequence of increased ACTH drive to the adrenal and identify novel molecular mechanisms that may lead to the development of hypertension within the general population.
Collapse
Affiliation(s)
- E M Freel
- Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, G12 8TA, UK.
| | | | | | | | | | | | | |
Collapse
|
50
|
Abstract
OBJECTIVE To observe the outcome in a group of children with undescended testes (UDT) given prolonged human chorionic gonadotrophin (hCG) stimulation as part of their management. STUDY DESIGN Retrospective review of 16 prepubertal boys given intramuscular hCG, 1500 U, on Days 1, 2 and 3 and then twice a week for 2 weeks with assessment of serum testosterone (T), SHBG, dihydrotestosterone (DHT) and androstenedione (A) on Days 1, 4 and 22. RESULTS In seven boys (44%), peak rise in T was by Day 4; in 5 boys (31%), the rise was by Day 22 and in the remainder, serum T stayed low. The median Day1 testosterone : androstenedione (T : A) ratio rose from 0.4 (range 0.2-1.5) to 1.7 (range 0.2-5.3) at Day 4 (P < 0.05) with no further rise by Day 22. The median dihydrotestosterone : testosterone ratio (DHT : T) at Day 1 and Day 4 remained unchanged. SHBG levels were more likely to be lower at Day 22 than at Day 4. The mean testosterone : SHBG (T : SHBG) ratio as a marker of androgen sensitivity was 0.2 (1SD 0.1). Bilateral testicular descent deemed immediate surgery unnecessary in 3 out of 15 (20%) boys where outcome data were available. CONCLUSION Whilst a 3-day hCG stimulation regimen may exclude 17beta-hydroxysteroid dehydrogenase-3 and 5alpha-reductase deficiencies, some boys with cryptorchidism may require more prolonged stimulation to assess androgen production and sensitivity. The possibility that this regimen leads to a reduced need for orchidopexy requires further exploration.
Collapse
Affiliation(s)
- J Dixon
- Department of Child Health, Royal Hospital for Sick Children, Glasgow, Scotland, UK
| | | | | | | |
Collapse
|